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ABSTRACT 
Steatosis is fat deposition in liver arising from conditions like obesity, diabetes, 
and/or alcohol consumption.  It is a benign condition with normal liver function, 
and can often be reversed.  Both alcoholic and non-alcoholic liver steatosis 
can further progress to irreversible steatohepatitis to cirrhosis and substantial 
loss of liver function.  Nuclear factor E2 related factor 2 (Nrf2) is a transcription 
factor known to combat oxidative stress in the cell.  The contribution of Nrf2 to 
other cellular functions, such as lipid homeostasis is emerging.  The work 
herein assessed how enhanced Nrf2 activity impacts progression of hepatic 
steatosis with long-term high fat diet (HFD) feeding.  C57BL/6 and Keap1-
Knockdown (Keap1-KD) mice, which exhibit enhanced Nrf2 activity, were fed a 
HFD for 24 weeks.  Keap1-KD mice had higher body weight, liver weight and 
higher hepatic fat deposition.  Lipogenic gene expression was also higher in 
livers of Keap1-KD mice fed HFD.  Next, the work herein studied effect of 
steatosis and cirrhosis on Nrf2 and drug transporter expression in human 
livers.  Transporters aid in hepatobiliary excretion of many drugs and toxic 
chemicals, and can be determinants of drug-induced liver injury.  Alcohol 
cirrhosis increased efflux transporter mRNA and protein expression in human 
livers as compared to normal non-steatotic livers.  It was observed that 
transporter expression alterations with steatosis were much less severe as 
compared to cirrhosis.  In order to demonstrate the effects of these drug 
transporter and metabolizing enzyme alterations on pharmacokinetics, we 
conducted oral Bisphenol A (BPA) disposition study in diet-induced obese 
mice.  The mice were administered deuterated BPA orally and blood levels 
were detected for BPA and BPA metabolites at times after BPA administration.  
Increased BPA clearance was observed in DIO mice, as compared to lean 
controls, attributed to increased phase II conjugation enzyme Ugt and biliary 
efflux transporter Abcc2 expression.  
In conclusion, constitutive activity of Nrf2 increases susceptibility to mice to 
develop liver steatosis; and human livers with steatosis and alcohol cirrhosis 
have altered expression of drug transporters, which may result in xenobiotic 
disposition alterations.   
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PREFACE 
The following dissertation titled “Role of nuclear factor E2 related factor 2 
(Nrf2) in development of steatosis and drug transporter alterations” is 
presented in manuscript format.  There are four manuscripts in this 
dissertation.  First manuscript is introductory and serves as a general 
background for manuscript two, three and four.  Manuscript two is formatted in 
Free Radical Biology and Medicine (FRBM) journal style, third manuscript is in 
Drug Metabolism Disposition (DMD) style, and fourth is in J Biochemical 
Molecular Toxicology (JBMT) style.  Manuscripts two and three are published 
in peer-reviewed journals as of March 2013.   
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MANUSCRIPT 1: 
NUCLEAR FACTOR E2 RELATED FACTOR 2 (NRF2) IN NON-ALCOHOLIC 
AND ALCOHOLIC LIVER DISEASE 
 
Vijay R More and Angela L Slitt 
 
Biomedical and Pharmaceutical Sciences, University of Rhode Island, 
Kingston, RI 
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NRF2:  
Nuclear factor E2 related factor 2, Nrf2, is a transcription factor very well 
known for combating oxidative stress by inducing a battery of antioxidant 
genes.  Nrf2 protects against oxidative stress at baseline levels, as well as, 
upon challenge by reactive oxygen species (ROS).  ROS are integral part of 
normal physiological mechanisms.  However, loss of redox balance causes 
generation of excess ROS, which can lead to cytotoxicity (1).   ROS play a 
vital role in pathogenesis of variety of diseases, such as cirrhosis, diabetes, 
hypertension, and cancer, along with neurological disorders including 
Parkinson’s disease (2), and Schizophrenia (3).  As reviewed by Naik and Dixit 
(2011), ROS can also lead to deregulated inflammation, arising from 
production of pro-inflammatory cytokines (4). 
 
Kelch like associated protein 1 (Keap1) acts as an inhibitor of Nrf2 by 
preventing its entry into nucleus to interact with antioxidant response element 
(ARE) (Fig. 1) (5).  Keap1 contains multiple cysteine residues in its structure, 
which are excellent sites for electrophillic attack.  The hinge and latch model 
described that one molecule of Nrf2 is sequestered to two molecules of 
Keap1, with one having more affinity for Nrf2 than other.  Upon induction, the 
loose interaction between Nrf2 and one of the Keap1 is broken, and stronger 
one remains intact.   Because of this structural modification of protein 
complex, degradation of Nrf2 by proteosome 26S is inhibited.  This results in 
! $!
Nrf2 accumulation to the extent that passes sequestering capacity of Keap1, 
and excess Nrf2 moves to nucleus (6).   
 
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD):  
Owing to increasing prevalence of obesity and diabetes, NAFLD is becoming 
the most common liver disease (7).  Youssef and McCullough reviewed the 
connections between obesity and NAFLD (8).  The prevalence of NAFLD is 
10-fold more in obese patients than in general population.  Non-alcoholic 
steatohepatitis (NASH) is severe form of NAFLD, which can progress to 
fibrosis and cirrhosis.  Insulin resistance is considered as key pathogenic 
factor in progression of NASH (9).  NASH, the most severe form of NAFLD, is 
known to develop by two “hits” (10).  The first hit is steatosis, which is fat 
deposition in liver, followed by second hit involving oxidative stress.  Even 
though progression of liver from steatosis to NASH is incompletely 
understood, it is clear that oxidative stress plays the major role in the process 
(11).  So, it is likely that Nrf2 exerts its protective actions in the second hit of 
the NASH, but acting to bolster expression of genes that encode for 
cytoprotective enzymes, which can counter oxidative stress, such as 
glutathione cysteine ligase, superoxide dismutase, and glutathione 
peroxidase.  However, very little is known about whether Nrf2 plays any role in 
steatosis, the first hit of NASH. 
! %!
ALCOHOLIC FATTY LIVER DISEASE: 
Alcoholic liver disease is a spectrum of conditions ranging from simple 
steatosis to alcoholic steatohepatitis to alcoholic cirrhosis.  Similar to obesity 
driven steatosis, alcoholic steatosis is also a reversible condition, and can be 
suppressed by abstinence from alcohol (12).  Continued consumption of larger 
quantities of alcohol causes increase in inflammatory cytokine levels, 
increased bile acid levels in liver, leading to alcoholic hepatitis.  There is 
severe hepatocyte ballooning because of excessive amount of water (13).  
There is increase in oxidative stress in the liver, and this may lead to fibrosis of 
liver.  Excessive scar tissue formation leads to cirrhotic liver, wherein 
significant loss of liver function occurs.  Alcoholic cirrhosis is completely 
irreversible damage of the liver tissue, and eventually leads to liver failure (13).   
According to Center for Disease Control and prevention (CDC), more than 
15,000 Americans die every year from alcoholic liver cirrhosis (National Vital 
Statistics Report, Volume 60, No 3).   
About 30% of cirrhotic patients also suffer from diabetes (14).  Acute, as well 
as chronic alcohol consumption leads to development of insulin resistance, 
which can progress to diabetes mellitus (15).  Disruption of normal functions of 
the liver in cirrhosis may lead to hepatogenous diabetes (16).  Additionally, 
obesity and diabetes mellitus increase the severity of alcoholic liver disease 
(17).  Owing to interplay between diabetes and cirrhosis, the two conditions 
often co-present clinically (18).    
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2.1 Abstract 
The Nuclear factor-E2 related factor 2 (Nrf2)-Kelch-like ECH-associated 
protein 1 (Keap1) pathway upregulates antioxidant and biotransformation 
enzyme expression to counter cellular oxidative stress.  The contribution of 
Nrf2 to other cellular functions, such as lipid homeostasis is emerging.  The 
present study was conducted to determine how enhanced Nrf2 activity impacts 
progression of metabolic syndrome with long-term high fat diet (HFD) feeding.  
C57BL/6 and Keap1-Knockdown (Keap1-KD) mice, which exhibit enhanced 
Nrf2 activity, were fed a HFD for 24 weeks.  Keap1-KD mice had higher body 
weight and white adipose tissue mass compared to C57BL/6 mice on HFD, 
along with increased inflammation and lipogenic gene expression.   HFD 
feeding increased hepatic steatosis and inflammation to a greater extent in 
Keap1-KD mice compared to C57BL/6 mice, which was associated with 
increased liver Cd36, fatty acid binding protein 4 (Fabp4), and monocyte 
chemoattractant protein 1 (Mcp1) mRNA expression, as well as, increased 
acetyl CoA carboxylase 1 (Acc1) and Steroyl CoA desaturase 1 (Scd1) protein 
expression.  The HFD altered short-term glucose homeostasis to a greater 
degree in Keap-KD mice compared to C57BL/6 mice, which was accompanied 
by down regulation of Insulin receptor substrate 1 mRNA expression in 
skeletal muscle.  Together, the results indicate that Keap1 knockdown, on 
treatment with HFD, increases certain markers of metabolic syndrome.  
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2.2 Introduction 
Metabolic syndrome is described as a cluster of risk factors that increase risk 
for developing cardiovascular disease [1].  Some of the risk factors include 
central obesity, atherogenic dyslipidemia (elevated triglycerides and low HDL 
cholesterol), insulin resistance (with or without glucose intolerance), and a 
proinflammatory state.  In 2003-2009, in an analytic sample that consisted of 
3,423 adults, 20 years of age and over, 34% of American adults met the 
criteria for metabolic syndrome [2]. 
Nuclear factor E2 related factor 2 (Nrf2) is a basic leucine zipper transcription 
factor, which regulates basal and inducible expression of multiple antioxidant 
and biotransformation genes [3].  Kelch-like ECH-associated protein 1 (Keap1) 
is a cysteine rich protein that binds Nrf2 in the cytosol, and is a critical 
determinant for Nrf2 nuclear accumulation.  Dose-dependent accumulation of 
Nrf2 in nucleus and increasing Nrf2 target gene expression occurs in Nrf2-
knockout, Keap1-knockdown and liver-specific Keap1 knockout mice [4].  The 
effects of Nrf2 and Keap1 knockout/knockdown are well described in models 
of liver injury caused by acetaminophen, diquat, cadmium, alcohol, or 
oxidative stress [5-10].  But the effects are largely undescribed for 
hyperlipidemia and tissues important to metabolic syndrome, such as adipose 
tissue and skeletal muscle (SKM). 
Central obesity is a major hallmark of metabolic syndrome.  Multiple nuclear 
receptors influence stem cell differentiation to adipocytes and adipocyte 
maturation. For example, multiple CCAAT-enhancer-binding protein isoforms 
! 11 
(Cebp! and Cebp") are required at various stages of adipocyte differentiation 
[11].  Peroxisome proliferator-activated receptor-gamma (Ppar-#) is known as 
a key regulator of fat synthesis, which regulates additional genes that 
contribute to lipid storage, such as Fatty acid binding protein 4 (Fabp4), 
Cluster of Differentiation 36 (Cd36, fatty acid translocase), Lipoprotein lipase 
(Lpl) and steroyl CoA desaturase (Scd1) [12].  Acetyl CoA carboxylase 1 
(Acc1) catalyzes formation of malonyl CoA, which is a vital substrate for fatty 
acid biosynthesis [13].  Malonyl CoA also inhibits "-oxidation of fatty acids.  
Phosphorylated Acc1 (pAcc1) is an inactive form of Acc1.  Fatty acid synthase 
(Fas) uses precursors like acetyl CoA and malonyl CoA to synthesize long 
chain saturated fatty acids.  Steroyl CoA desaturase 1 (Scd1) catalyzes 
synthesis of unsaturated fatty acids from saturated fatty acids [13].  
Lipoprotein lipase (Lpl) breaks down triglycerides (TG) from lipoproteins to 
release free fatty acids [14].  In summary, all of the abovementioned enzymes/ 
enzyme complexes are responsible for fatty acid levels in the tissues as well 
as serum.     
Adipocytes function to not only store fat, but also produce and secrete 
‘adipocytokines’ that include bioactive products such as inflammatory 
mediators (e.g. Interleukin-6, IL-6; monocyte chemoattractant protein, Mcp1; 
tumor necrosis factor, Tnf), which are considered to be a cause of insulin 
resistance and non-alcoholic fatty liver disease [15, 16].  Obesity increases the 
presence of M1 pro-inflammatory macrophages in adipose tissue, increases 
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secretion of pro-inflammatory cytokines, and increases M1 hepatic 
macrophages and inflammation [17].   
In adipose tissue, Nrf2 binds to an ARE present in the Ppar-# promoter to 
promote adipocyte differentiation [18].  Nrf2 knockout mice were protected 
against hepatic steatosis induced by high fat diet (HFD) feeding [19], indicating 
that Nrf2 presence is needed for hepatic lipid accumulation.  Huang et al. 
(2010) illustrated that targeted Nrf2 deletion protects against high fat diet 
induced steatosis through dowregulation of Cd36, Sterol regulatory element 
binding protein 1c (Srebp-1c), Fas, Ppar-# expression, and upregulation of 
Small heterodimeric partner (Shp) -dependent pathways.  Moreover, OB-
Keap1KD exhibit increased hepatic steatosis compared to OB mice [20].  In 
contrast, Kay et al. (2011) report inverse that NRF2 and SREBP1c are 
inversely regulated in human livers with steatosis [21].  Because hepatic 
steatosis is a manifestation of metabolic syndrome, better understanding of 
Nrf2 function in hepatic lipid accumulation in the face of dyslipidemia is 
needed.   
 
The study herein describes the effect of chronic HFD-feeding on markers of 
metabolic syndrome including 1) WAT mass and hepatic steatosis, 2) glucose 
clearance, and 3) WAT and liver inflammation in C57BL/6 and Keap1-
knockdown mice.  Overall, Keap1-KD mice exhibited increased markers of 
metabolic syndrome with long-term HFD feeding. 
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2.3 Materials and methods 
2.3.1 Animals. Mice with Keap1 knockdown (Keap1-KD), congenic to 
C57BL/6 background were generously shared by Dr. Curtis Klaassen (Kansas 
University Medical Center, Kansas City, KS) and Dr. Masayuki Yamamoto 
(Tohoku University Graduate School of Medicine, Sendai, Japan).  The mice 
are described in multiple publications from Yamamoto and Klaassen [22-24].  
Male age-matched C57BL/6 and Keap1-KD mice were bred in-house and fed 
diet containing either 10% kcal fat (LFD, Research Diets Inc, D12450B) or 
60% kcal fat (HFD, Research Diets Inc, D12492) starting at wean (3 weeks) 
(n=4 or 5 per group).  Body weights were measured every week starting from 
six weeks of age (3 weeks on diet).  At the age of 27 weeks, blood, liver, SKM, 
and WAT, and brown adipose tissue were collected.  The study herein was 
reviewed and approved by the University of Rhode Island Institutional Animal 
Care and Use Committee (IACUC protocol # AN11-11-007) and the number of 
mice used was based upon required power analysis. 
 
2.3.2 Glucose tolerance test (GTT). The GTT was performed on the mice at 
25 weeks of age.  Mice were fasted for 8 hours overnight and were 
administered a bolus dose of glucose solution by oral gavage (1g/kg body 
weight).  The blood glucose levels were recorded at 0, 15, 30, 60, and 120 
minutes after glucose administration from tail blood using a Contour® 
glucometer (Bayer HealthCare LLC, Tarrytown, NY).   
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2.3.3 Hepatic triglyceride (TG) quantification. Total lipids were extracted 
from liver tissue by methanol-chloroform extraction according to [25] and TGs 
were quantified using a kit from Pointe Scientific Inc (Canton, MI) according to 
manufacturer’s protocol. 
 
2.3.4 Hematoxylin and Eosin staining. After harvesting, a small section of 
liver tissue from the central lobe of the liver, WAT, or brown adipose tissue 
was stored in formaldehyde for 24 hour and then in 75 % ethanol until further 
processing for paraffin embedding.  Paraffin-embedded tissues were cut to 
approximately 5 µm sections, and then stained with hematoxylin and eosin.   
 
2.3.5 Oil red O staining. Frozen liver tissues were sectioned (5µM) on 
Vibratome UltraPro 5000 Cryostat® (GMI Inc., Ramsey, MN).  Sections were 
then fixed in 10% formalin for 5 min and slides were washed in water.  Then 
slides were immersed in 60% isopropanol five times and incubated in Oil red 
O solution for 15 min.  The slides were immersed in fresh 60% isopropanol 
solution twice and then counter stained with hematoxylin.  Excess hematoxylin 
was removed with a water wash and the slides were covered using 
Vectamount aqueous solution and coverslips.     
 
2.3.6 Neutrophil staining. Neutrophil staining of paraffin embedded liver and 
WAT sections was performed as described in [26].  Briefly, 4 µM sections on 
adhesive slides were dried, de-paraffinized and placed in TBS of pH 7.5 for 5 
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min.  Enzyme Induced Epitope Retrieval (20 minutes in 0.04% Pepsin in 
0.2NHCl) followed by subsequent rinses and blocking for endogenous 
peroxidase using 3% Hydrogen Peroxide/Methanol bath (1:4 ratio) for 20 
minutes followed by rinses with water.  Pretreatment was followed by blocking 
with rabbit serum and endogenous Biotin blocking by incubation in Avidin D 
(Vector) and d-Biotin (SigmaAldrich, St.Louis, MO) for 15 minutes.  Slides 
were then incubated with primary antibodies diluted in normal diluent for 1 hr 
(Neutrophil- NIMP R14 from Santa Cruz Biotech, CA).  Biotinylated secondary 
antibody incubation was followed by RTU VectaStain Elite ABC Reagent 
(Vector Laboratories, Burlingame, CA), reaction developed by Nova Red 
followed by counterstain Gill 2 Hematoxylin (Richard Allen, Kalamazoo, MI).  
The slides were then rinsed, dried and permanently mounted with Flotex 
media.   
 
2.3.7 Serum cytokine analysis. Serum Mcp1 levels were measured using 
Mouse Mcp1 ELISA Max kit (# 432704) from Biolegend (San Diego, CA) 
according to the manufacturer’s protocol.   
   
2.3.8 Total RNA extraction and mRNA quantification. Total RNA from liver, 
WAT and SKM was isolated by phenol-chloroform extraction using RNA Bee 
reagent (Tel-Test Inc, Friendswood, TX) according to the manufacturer’s 
protocol. RNA concentration was quantified by absorbance at 260 nm using a 
spectrophotometer (Nanodrop ND1000, Thermo Fisher Scientific, Waltham, 
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MA) and the samples were diluted to 1 µg/µL. Formaldehyde–agarose gel 
electrophoresis followed by UV illumination was used to visualize RNA and 
confirm integrity.  Messenger RNA was quantified by QuantiGene (QGP) Plex 
2.0 or 1.0 assay.   
For QGP 2.0 assay, all the reagents including capture buffer, magnetic 
capture beads, preamplifier, amplifier, label probe, diluents, and substrate 
solution were provided in the kit (Affymetrix, Santa Clara, CA).  On day one, 
1000ng of RNA was incubated with capture beads and target specific probe 
set mixture for hybridization for 18-22 hrs.  After hybridization, the beads were 
washed on BioPlex Pro wash station I (BioRad, Hercules CA), using magnetic 
plate washer.  Then beads were hybridized with preamplifier, amplifier and 
label probe for 1 hr each and with washings in-between with wash buffer.  
After incubation with label probe, the beads were washed and incubated with 
streptavidin phycoerythrin (SAPE) for 30 min.  The beads were then washed 
with SAPE washing buffer and re-suspended in it for reading on Bioplex 
microplate luminometer.  The data was processed by BioPlex Manager 
software 5.0.  Target gene expression was normalized to Hprt1 expression.  
The QGP 1.0 assay (also referred to as the Branched DNA Signal 
Amplification assay) procedure has been described in detail elsewhere [27, 
28].  All reagents for analysis including lysis buffer, amplifier/label probe 
diluent and substrate solution were supplied in the QuantiGene 1.0 assay kit 
(Panomics, Fremont, CA). Oligonucleotides were first dissolved in 10 mM Tris-
HCl (pH 8.0) containing 1 mM EDTA and were diluted 1:100 in lysis buffer 
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before use [29].  On day one, total RNA samples (10 µg, 1 µg/µL) were added 
to wells containing 50 µL of capture hybridization buffer and 50 µL of diluted 
probe set. The RNA was allowed to hybridize overnight with probe set at 53°C. 
On day two, subsequent hybridization steps were followed as mentioned in 
manufacturer’s protocol, and luminescence was measured with a 
GloRunnerTM microplate luminometer interfaced with GloRunner DXL Software 
(Turner Biosystems, Sunnywale, CA). The luminescence for each well was 
reported as relative light units (RLU) per 10 µg of total RNA.  The raw data 
was used to plot graphs for mRNA expression.    
 
2.3.9 Total protein extraction and western blotting. About 50mg of liver 
tissue was homogenized in 1mL RIPA buffer using Dounce homogenizer.  The 
homogenate was centrifuged at 12000 rpm for 10 minutes, and the 
supernatant was stored at -80°C for future use as a total protein fraction.  The 
extract was quantified for protein content by Lowry assay.  Relative protein 
expression was evaluated by western blot. Fifty microgram of total protein 
extract pre-mixed with Laemmli was loaded on polyacrylamide gel (4% 
stacking, 12% resolving), transferred on PVDF membrane, stained with 
different antibodies.  All the primary antibodies were obtained from Cell 
Signaling Inc (Danvers, MA).  The membrane was then incubated with ECL+ 
(GE Healthcare, Waukesha, WI) and chemiluminescence was exposed to X-
ray film.  The resulting bands on autoradiography films were evaluated using 
Quantity One® software from BioRad.  
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2.3.10 Statistical Analysis. Groups were analyzed by a one-way ANOVA 
followed by a Duncan’s Multiple Range post hoc test and planned comparison 
between C57BL/6 and Keap1-KD groups were performed among HFD groups 
after performing the one-way ANOVA.  Different letters indicate statistically 
significant difference between the groups (p<0.05).   
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2.4 Results 
2.4.1 Effect of Keap1-KD on body, WAT, and liver weight and food 
consumption with long-term HFD feeding.  Figure 1A depicts body weight 
change over 24 weeks. There was no significant difference in body weight 
between C57BL/6 and Keap1-KD mice fed the LFD.   Keap1-KD mice fed HFD 
had significantly higher body weight between weeks 17-24, compared to 
C57BL/6 mice fed HFD.  At weeks 8 and 9, the HFD did not increase body 
weight in Keap1-KD mice as much as C57BL/6 mice.  However, around 11th 
week feeding the HFD, the trends in body weight gain appeared to reverse, 
with Keap1-KD mice having body weight higher than C57BL/6 mice.  Food 
consumption (Fig. 1B) for the LFD groups stayed within the range of 15-20 
g/week per mouse for entire duration of the study.  For HFD fed mice, it was 
noted that food consumption appeared slightly higher in C57BL/6, as 
compared to Keap1-KD mice throughout the study (no statistical significance).  
Blood glucose levels of the mice throughout the course of study were 
observed to remain in the range of 100 to 200 mg/dL, with no significant 
difference between any of the groups (data not shown). 
HFD feeding increased WAT weight (Fig 1C) significantly higher in Keap1-KD 
compared to C57BL/6 mice.  At 24 weeks of feeding the LFD or HFD, Keap1-
KD mice also had an increased liver-to- body weight ratio as compared to 
C57BL/6 mice on the respective diet. 
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2.4.2 Keap1 knockdown increases liver steatosis with chronic HFD 
feeding.  As depicted in Fig. 2A, the HFD increased lipid accumulation in the 
liver compared to the LFD. Keap1-KD mice fed the HFD had a higher degree 
of steatosis compared to C57BL/6 mice, as seen with hematoxylin and eosin 
staining.  Oil red O staining of neutral lipids also revealed that the HFD 
significantly increased hepatic steatosis, with higher levels being observed in 
Keap1-KD mice (Fig. 2B).  Correspondingly, the HFD increased hepatic 
triglycerides (Fig. 2C); with significantly higher TG levels being detected in 
livers of Keap1-KD mice compared to C57BL/6 mice.   
 
2.4.3 Keap1 knockdown increases lipogenic gene and protein expression 
in liver.  Fig. 3A depicts lipogenic gene expression on mRNA level in liver.  
Ppar-# and Cd36 mRNA expression increased significantly in Keap1-KD mice 
as compared to C57BL/6 mice, in both LFD and HFD fed groups.  Fabp4 
mRNA expression increased in Keap1-KD mice fed HFD compared to 
C57BL/6 mice.  Lpl mRNA expression was higher in C57BL/6 mice fed LFD 
compared to all other groups, whereas Scd1 expression remained unchanged 
between all the groups.  Fig. 3B and 3C depicts increased mRNA expression 
of Nrf2 and its target genes, NADPH quinone oxidoreductase (Nqo1) and 
glutamate cysteine ligase, catalytic subunit (Gclc) in livers and WAT of Keap1-
KD mice.  Expression of Nrf2 and its target genes was quantified in order to 
characterize the Keap1-KD model. 
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Protein expression of similar adipogenic targets also tended to increase livers 
of Keap1-KD mice fed HFD (Fig. 4).  HFD slightly increased Ppar$# protein 
expression in Keap1-KD mice, however the change did not reach statistical 
significance.  Phosphorylated acetyl CoA carboxylase 1 (pAcc1), Acc1, and 
Scd1 protein levels were increased in Keap1-KD mice fed HFD compared to 
C57BL/6 mice.  Fatty acid synthase (Fas) protein expression was equivalent 
among all groups; however, HFD groups displayed an increasing trend in 
expression (not statistical), as compared to LFD.   
 
2.4.4 Keap1-KD increases liver and WAT tissue inflammation. Neutrophil 
staining of paraffin-embedded liver sections revealed increased infiltration in 
the HFD fed mice, with even more neutrophils in Keap1-KD mice fed HFD 
(Fig. 5A).  Serum levels of Mcp1 tended to increase in Keap1-KD mice fed 
either LFD or HFD, but this did not achieve statistical significance (Fig. 5B).  
Quantification of relative pro-inflammatory cytokine mRNA expression in liver 
tissue supported the histological staining.  Mcp1 mRNA expression in liver was 
higher in Keap1-KD compared to C57BL/6 mice fed HFD (Fig. 5C).  Tnf mRNA 
expression remained constant between C57BL/6 and Keap1-KD mice fed 
same diet. 
Chronic feeding of the HFD caused increased cellularity in WAT (Fig. 6A), 
which is often associated with presence of neutrophils and macrophages [30].  
After chronic HFD feeding, WAT from Keap1 mice had increased cellularity 
and inflammation compared to C57BL/6 mice, as determined by 
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histopathological analysis.  Messenger RNA levels of proinflammatory 
macrophage M1-marker Tnf was elevated in WAT of Keap1-KD mice fed HFD 
as compared to C57BL/6 mice fed HFD (Fig. 6B).  Mcp1 and Cd11c mRNA 
levels were higher in HFD fed groups, but there was no significant difference 
between the C57BL/6 and Keap1-KD mice. 
 
2.4.5 Keap1-KD alters glucose clearance and insulin signaling protein 
expression in SKM.  After 23 weeks of feeding the LFD or HFD, mice were 
subjected to a glucose tolerance test (GTT), as a measure of diabetes and 
insulin resistance.  No differences in glucose levels after glucose 
administration were detected between C57BL/6 or Keap1-KD mice fed the 
LFD. Mice fed the HFD had higher blood glucose levels compared those fed 
the LFD.  After 15, 30 and 60 min of glucose administration, the blood glucose 
levels of Keap1-KD mice fed HFD were about 1.5 fold higher compared to 
C57BL/6 mice fed the HFD (Fig. 7A).  Area under the curve (AUC) for GTT 
also demonstrated that blood glucose levels remained significantly high in 
Keap1-KD mice fed HFD as compared to C57BL/6 mice fed HFD (Fig. 7B) for 
the duration of 2 hrs. 
In accordance with the GTT, the expression of insulin signaling target insulin 
receptor substrate 1 (Irs1) was also down regulated in SKM.  In HFD fed mice, 
Keap1-KD mice had decreased mRNA expression of Irs1 compared to 
C57BL/6 mice (Fig. 7C).  However, Glut4 mRNA and protein expression was 
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similar between all the groups, as determined by QGP 2.0 assay and western 
blot respectively (Fig. 7C and 7D).     
! 24 
2.5 Discussion 
Metabolic syndrome is considered to be a manifestation of obesity, 
characterized by increased central abdominal mass, dyslipidemia (e.g. 
increased serum triglycerides), increased hepatic steatosis and markers of 
systemic inflammation, and dysregulation of glucose tolerance [31].  To date, 
no study has evaluated the effect of Keap1 knockdown on development of 
metabolic syndrome.  The present study demonstrates that Keap1 knockdown 
increased some markers of metabolic syndrome after long term HFD feeding.  
Along with increased body weight and WAT mass, Keap1-KD mice fed a HFD 
displayed increased hepatic and white adipose markers of inflammation, 
hepatic steatosis, increased adipose cellularity, and altered glucose 
homeostasis.  Taken together, these data suggest that Keap1 knockdown, 
and perhaps persistent Nrf2 activation, are associated with increased 
metabolic syndrome risk with HFD challenge.   
The present data indicate that Keap1-KD mice had significantly higher body 
weight and adipose tissue mass compared to C57BL/6 mice with chronic long-
term HFD feeding, which are in line with other published findings.  Pi et al. 
described adipose tissue changes in Nrf2-/- mice [18].  The body weight of 
Nrf2-/- mice was significantly lower than wild type mice fed an ad libitum diet.  
Abdominal fat pad mass, and adipocyte size was also significantly smaller in 
mice with Nrf2-/- mice.  Nrf2-/- mice were also resistant to diet-induced obesity, 
when fed 41% kCal fat diet for 12 weeks after weaning.  Also, adipocytes 
derived from Nrf2-/- mouse embryonic fibroblasts accumulated less lipids 
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compared to those derived from Nrf2+/+ mouse embryonic fibroblasts [18]. 
Another study by Huang et al. also demonstrated that deletion of Nrf2 (Nrf2-/-) 
in mice resulted in reduced body weight in Nrf2-/- mice fed a HFD for 
approximately three months.  These mice also had lower hepatic TG content 
when challenged with HFD, compared to Nrf2+/+ mice [19].  Nrf2-/- mice 
displayed better insulin sensitivity, measured by glucose tolerance, as 
compared to wild type mice fed HFD for 180 days [32].  The data herein also 
demonstrate that Keap1-KD mice display increased hepatic steatosis 
compared to C57BL/6 mice.  It was observed that the HFD increased hepatic 
lipid accumulation along with increased lipogenic gene and protein expression 
(e.g. Fabp4 mRNA, Cd36 mRNA, pAcc1 protein), which was augmented in 
Keap1-KD mice.  This observation is consistent with a report by Huang et al., 
2010, which reported decreased hepatic lipid accumulation in livers of Nrf2-/- 
mice after long term HFD feeding.  An interesting change in body weights was 
noted in the HFD fed groups.  Up to about 8-9 weeks of feeding the HFD, 
C57BL/6 mice appeared to have significantly higher body weight as compared 
to Keap1-KD mice, which is consistent with our previous observation [33].  
However, this difference diminished at about 11 weeks of feeding HFD and 
then by 19 weeks of HFD feeding, Keap1-KD mice weighed significantly 
higher than C57BL/6.  Food consumption did not significantly differ between 
genotypes, suggesting the observed increase in metabolic syndrome markers 
in Keap1-KD mice are related to lipid metabolism and not appetite.  Zhang et 
al. recently reported no alterations in body and liver weights in Keap1-KD mice 
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fed 40% kCal fat diet for 12 weeks [34].  The results herein differ from Zhang 
et al., perhaps because our study used 60% kCal fat diet and was significantly 
longer in duration.  However, our results are consistent with Zhang et al. and 
Xu et al., when duration of feeding is considered.  For example, in the present 
study, body weights were similar between C57BL/6 and Keap1-KD mice after 
12 weeks of HFD feeding (15 weeks of age), which is consistent with Zhang et 
al. Also, our group reported that Keap1 knockdown protected against HFD-
increased weight gain [33], which on a cursory review seems inconsistent with 
the present study.  Again, when one evaluates the response of Keap1-KD 
mice with regard to duration on a HFD, the present data are also consistent 
with Xu et al.  In Xu et al., HFD feeding started at 9 weeks of age for 5 weeks 
in duration.  In the present study, Keap1-KD mice had lower body weights 
compared to C57BL/6 mice on the HFD after 5 weeks of feeding, consistent 
with Xu et al [33].  It appears that short term versus long term HFD in Keap1-
KD produce different outcomes with regard to body weight.  
In contrast to the present finding, others report that activation of Nrf2 is 
protective against HFD-induced obesity and steatosis, but this is typically 
reported in conjunction with pharmacological Nrf2 activating compounds.  
Chemical activators of Nrf2 including, oltipraz, CDDO-imidazole, and 
sulforaphane in separate studies protected mice against obesity and steatosis 
[21, 35, 36].  When administered with oltipraz, HFD feeding did not have 
obesogenic effects on mice for up to 28 weeks.  Body weight, liver weight and 
adipose tissue weight gain induced by HFD feeding was prevented with 
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oltipraz co-administration C57BL/6J mice [35].  Similarly, the synthetic 
triterpenoid CDDO-imidazole also prevented weight gain in mice fed HFD for 3 
and 13 weeks [36].  In an experiment with hepatocytes, Nrf2 activator 
sulforaphane suppressed Liver X receptor (Lxr) dependent steatosis [21].  It is 
not clear why pharmacological Nrf2 activators impact HFD feeding differently 
compared to genetic models of Nrf2 manipulation, but perhaps other receptor 
systems (e.g. Constitutive Androstane Receptor and Pregnane x receptor) 
might also be activated [24, 37].  One must also consider the absorption, 
metabolism, and disposition of the chemical inducers being administered in 
comparison to a genetically manipulated mouse model that has whole body 
Keap1 knockdown. 
The present study also demonstrated that constitutive Nrf2 activation altered 
glucose homeostasis.  As GTT is an indicator of sensitivity of cells to respond 
to insulin action, ability of pancreas to produce insulin and ability of liver to 
store glucose, expression of insulin responsive targets in the SKM could 
partially explain the reason for the insulin intolerance.  SKM is one of the major 
glucose utilizing tissues in the body and Glut4 is a predominant glucose 
transporter responsible for insulin stimulated glucose uptake in SKM [38].  
Keap1-KD mice fed the HFD had unaltered mRNA and total protein 
expression of Glut4.  However, the mRNA expression of Irs1 mRNA, a protein 
involved in molecular basis for action of insulin [39], was decreased in Keap1-
KD mice fed the HFD, supporting data obtained from GTT in Keap1-KD mice. 
It is possible that glucose uptake in skeletal muscles was not altered in Keap1-
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KD mice fed HFD due to total Glut4 protein expression.  Glut4 translocation to 
the membrane or defects in Irs-1 or Akt phosphorylation in response to 
glucose or insulin could also be potentially considered.  The Keap1-KD mice 
fed HFD demonstrate a disturbance in glucose homeostasis with glucose 
challenge, which does suggest a potential for development of insulin 
resistance.  
 
Adipocytes act as endocrine cells, secreting variety of adipocytokines 
including leptin, adiponectin, as well as interleukins [40].  In genetic and diet-
induced obese mouse models, the expression of inflammation and 
macrophage markers was increased in WAT of obese compared non-obese 
mice [41].  Inflammation is one of the most critical etiological factors in 
development of insulin resistance [42, 43].  The current data illustrate that the 
Keap1-KD mice fed the HFD had increased measures of inflammation in WAT 
and liver.  Both WAT and liver had increased inflammation, as noted by 
increased cellularity (WAT) and neutrophil staining (NIMP R14, Liver).  HFD 
fed Keap1-KD mice were found to have higher levels of cytokines levels in 
serum and higher expression of cytokine mRNA in liver, as compared to C57 
mice fed HFD.  Expression of pro-inflammatory M1 macrophage markers was 
higher in Keap1-KD mice fed HFD, indicating possible role of long term Nrf2 
activation in inflammation.   
The reason why increased Nrf2 activation might promote lipogenesis and 
inflammation with HFD feeding is intriguing.  It remains to be determined 
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whether lipid accumulation preceded inflammation, but it is likely.  Nrf2 has 
been shown to be a positive regulator of the mouse Ppar-# promoter, increase 
Ppar-# expression, and promote adipogenesis [18], with a similar mechanism 
occurring in liver [33].  Thus, the persistent Nrf2 activation in liver appeared to 
promote lipid accumulation via upstream Ppar-# activation.  Perhaps an 
increased biotransformation due increased Nrf2 activity resulted in increased 
lipids that caused tissue injury and inflammation.  The data clearly 
demonstrate increased inflammation in liver and WAT, yet an underlying 
mechanism for the increased inflammation remains to be determined. 
 
Along with Nrf2, Keap1 is also implicated to interact with Nrf1 [44].  Nrf1, like 
Nrf2, also belongs to basic leucine zipper family of transcription factors.  It 
plays a role in combating oxidative stress by increasing glutathione levels [45].  
However, a review by Biswas and Chan mentioned that functions of Nrf1 and 
Nrf2 are not completely redundant [46].  Nrf1 also plays role in regulating 
inflammatory targets including inducible nitric oxide synthase [46].  Although 
Keap1 has much lower affinity for Nrf1 compared to Nrf2 [47], it is still possible 
that Keap1-KD mice would have slightly increased levels of Nrf1.  The effect of 
Nrf1 on obesity/ diabetes is a relatively under-investigated area.  
    
Our results herein are also of relevance to the study of obesogenic 
compounds, as the Nrf2 pathway is inducible and functional in adipose tissue 
and skeletal muscle [33] and Nrf2 is activated by multiple environmental 
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chemicals [48].  Thus, it is of potential interest to better understand whether 
Nrf2 activation via environmental chemical could intersect with obesogenic or 
pro-metabolic syndrome effects via environmental chemical exposure [49].  In 
summary, the data herein demonstrate that Keap1-KD mice, which have 
Keap1 knocked down and constitutive Nrf2 activation, were susceptible to 
increased markers of metabolic syndrome, such as diet-induced obesity, 
hepatic steatosis, and glucose intolerance concomitant with increased in 
inflammation in liver and adipose tissue, after long-term HFD feeding.  Overall, 
this study suggests that Nrf2 has a role beyond combating oxidative stress 
and further investigation is needed to better understand Nrf2-Keap1 
interactions with chronic HFD challenge.
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2.7 Figure legends 
Figure 1. Body, liver and WAT weight and adipocyte size of C57BL/6 and 
Keap1-KD mice fed a 10% kCal low fat diet (LFD) or 60% kCal high fat 
diet (HFD). A) Body weights (starting from age 6 weeks) and B) food 
consumption of C57BL/6 (C57) and Keap1-KD mice fed a LFD or HFD from 
weaning age to 27 weeks (starting at age 6 weeks).  C) Abdominal adipose 
tissue weight and liver to body weight ratio.  Differences between the groups 
were analyzed by a one-way ANOVA followed by a Duncan’s post hoc test.  
Different letters indicate statistically significant difference between the groups 
(p<0.05).  For example, letter “a” is significantly different from “b”, but not 
different from “a”.  Also, “a” is significantly different from “b,c” but not different 
from “a,b”. 
 
Figure 2. Hepatic lipid accumulation and triglyceride (TG) content in 
C57BL/6 (C57) and Keap1-KD mice fed a 10% kCal low fat diet (LFD) or 
60% kCal high fat diet (HFD).  A) Hematoxylin and eosin staining of 
formaldehyde fixed paraffin embedded liver tissues (200X magnification).  B) 
Oil red O staining of liver sections.  Frozen liver tissues were sectioned in 5µm 
sections, stained with Oil red O, and counter stained with hematoxylin (200X 
magnification).  C) Hepatic TG content.  Lipids were extracted using a 
methanol-chloroform based protocol and the resulting TG content was 
assayed using kit from Pointe Scientific (Canton, MI).  Differences between the 
groups were analyzed by a one-way ANOVA followed by a Duncan’s post hoc 
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test.  Different letters indicate statistically significant difference between the 
groups (p<0.05).   
Figure 3. Lipogenic, Nrf2, and Nrf2 target gene expression in livers and 
white adipose tissue (WAT) of C57BL/6 (C57) and Keap1-KD mice fed a 
10% kCal low fat diet (LFD) or 60% kCal high fat diet (HFD).  Total RNA 
was extracted from the livers by phenol-chloroform extraction and mRNA was 
quantified using Quantigene Plex 2.0 or Branched DNA Signal Amplification 
assay (Affymetrix, Santa Clara, CA).  A) Peroxisome proliferator activated 
receptor ! (Ppar-#), Steroyl CoA desaturase (Scd1), Fatty acid binding protein 
4 (Fabp4), Lipoprotein lipase (Lpl), and Cluster of differentiation (Cd36) mRNA 
expression.  B) Nrf2, NADPH:quinone oxidoreductase (Nqo1), glutamate 
cysteine ligase (Gclc) mRNA expression in liver.  C) Nrf2 and Nqo1 mRNA 
expression in WAT.  Differences between the groups were analyzed by a one-
way ANOVA followed by a Duncan’s post hoc test.  Different letters indicate 
statistically significant difference between the groups (p<0.05).  For example, 
letter “a” is significantly different from “b”, but not different from “a”.  Also, “a” is 
significantly different from “b,c” but not different from “a,b”. 
  
 
Figure 4. Protein expression of lipogenic enzymes in livers of C57BL/6 
(C57) and Keap1-KD mice fed a 10% kCal low fat diet (LFD) or 60% kCal 
high fat diet (HFD).  A) Western blots for lipogenic enzymes in liver.  Total 
protein extracts were separated on polyacrylamide gel, immunoblotted, and 
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chemiluminescence was captured on X-ray films.  B) Western blot 
quantification.  The resulting blots obtained were evaluated using Quantity 
One® software (Biorad, Hercules, CA) and band density is plotted as percent 
of C57BL/6 fed LFD.  Differences between the groups were analyzed by a 
one-way ANOVA followed by a Duncan’s post hoc test.  Different letters 
indicate statistically significant difference between the groups (p<0.05).   
 
Figure 5. Inflammatory markers in liver and serum of C57BL/6 (C57) and 
Keap1-KD mice fed a 10% kCal low fat diet (LFD) or 60% kCal high fat 
diet (HFD).  A) Neutrophil (NIMP R14) staining of paraffin embedded liver 
sections.  Images displayed in 200X magnification.  B) Serum cytokine 
Monocyte chemoattractant protein 1 (Mcp1) levels C) mRNA expression of 
inflammatory cytokine markers Mcp1, Tumor necrosis factor (Tnf) and Cd11c 
in liver.  Total RNA was extracted from liver tissue by phenol-chloroform 
extraction and mRNA was quantified using Quantigene Plex 2.0 assay 
(Affymetrix, Santa Clara, CA).  For statistical significance, groups were 
compared by one-way ANOVA followed by a Duncan’s post hoc test.  Different 
letters indicate statistically significant difference between the groups (p<0.05). 
 
Figure 6. White adipose tissue (WAT) cellularity and inflammation in 
C57BL/6 (C57) and Keap1-KD mice fed a 10% kCal low fat diet (LFD) or 
60% kCal high fat diet (HFD).  A) Hematoxylin and eosin stained sections of 
paraffin embedded WAT.  Images displayed in 200X magnification.  B) 
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Messenger RNA expression of proinflammatory macrophage markers 
monocyte chemoattractant protein 1 (Mcp1), tumor necrosis factor (Tnf) and 
Cd11c in WAT.  Differences between the groups were analyzed by a one-way 
ANOVA followed by a Duncan’s post hoc test.  Different letters indicate 
statistically significant difference between the groups (p<0.05). 
 
Figure 7. Glucose tolerance test (GTT) and expression of insulin 
signaling molecules in skeletal muscle (SKM) of C57BL/6 (C57) and 
Keap1-KD mice fed a 10% kCal low fat diet (LFD) or 60% kCal high fat 
diet (HFD).  A) GTT after 23 weeks of LFD or HFD treatment.  Mice were 
fasted overnight and challenged with an oral glucose bolus (1g/kg).  Blood 
glucose levels were recorded at 0, 15, 30, 60, and 120-minute time points 
using Contour® glucose meter (Bayer HealthCare LLC, Tarrytown, NY).  
*Represents statistically significant difference of glucose levels between 
C57BL/6 and Keap1-KD mice fed same diet.  B) Area under the curve (AUC) 
plotted for the GTT.  C) Messenger RNA expression of insulin receptor 
substrate 1 (Irs1) and glucose transporter Glut4 in SKM.  Total RNA was 
extracted from liver tissue by phenol-chloroform extraction and mRNA was 
quantified using Quantigene Plex 2.0 assay (Affymetrix, Santa Clara, CA).  For 
parts Differences between the groups were analyzed by a one-way ANOVA 
followed by a Duncan’s post hoc test.  Different letters indicate statistically 
significant difference between the groups (p<0.05).  For example, letter “a” is 
significantly different from “b”, but not different from “a”.  Also, “a” is 
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significantly different from “b,c” but not different from “a,b”.  D) Protein 
expression of Glut4 from skeletal muscle of C57BL/6 and Keap1-KD mice fed 
LFD and HFD by western blot (n=2 per group).   
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3.1 Abstract 
Unsafe use of alcohol results in approximately 2.5 million deaths worldwide, 
with cirrhosis contributing to 16.6% of reported deaths.  Serum insulin levels 
are often elevated in alcoholism, which may result in diabetes; which is why 
alcoholic liver disease and diabetes often are co-present.  Because there is a 
sizable population that presents with these diseases alone or in combination, 
the purpose of this study was to determine whether transporter expression in 
human liver is affected with alcoholic cirrhosis, diabetes, and alcohol cirrhosis 
co-existing with diabetes.  Transporters aid in hepatobiliary excretion of many 
drugs and toxic chemicals, and can be determinants of drug-induced liver 
injury.  Drug transporter and transcription factor relative mRNA and protein 
expression in normal, diabetic, cirrhotic and cirrhosis with diabetes human 
livers were quantified.  Cirrhosis significantly increased ABCC4, 5, ABCG2 
and SLCO2B1 mRNA expression, and decreased SLCO1B3 mRNA 
expression in liver.  ABCC1, 3-5, ABCG2 protein expression was also 
upregulated by alcohol cirrhosis.  ABCC3-5, and ABCG2 protein expression 
was also upregulated in diabetic-cirrhosis.  Cirrhosis increased NRF2 mRNA 
expression, whereas it decreased PXR and FXR mRNA expression in 
comparison to normal livers.  Hierarchical cluster analysis indicated that 
expressions of ABCC2, 3 and 6; SLCO1B1 and 1B3; and ABCC4 and 5 were 
more closely related in the livers from this cohort.  Overall, alcohol cirrhosis 
altered transporter expression in human liver.   
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3.2 Introduction 
Hepatobiliary excretion is an integral function necessary to excrete bile acids, 
bilirubin, conjugated hormones, as well as, drugs and chemicals from liver 
(Klaassen and Aleksunes, 2010).  The process of biliary excretion relies upon 
membrane bound transporters localized to hepatocytes, which extract 
chemicals from blood and efflux chemicals into bile.  The solute carrier organic 
anion (SLCO) and ATP-Binding Cassette (ABC) transporter families comprise 
two major families that mediate hepatic uptake and efflux processes. 
 
SLCO transporters are often described as “uptake transporters”, because they 
are predominantly localized to the sinusoidal membrane and typically extract 
chemicals from blood into hepatocytes (reviewed by (Klaassen and Aleksunes, 
2010)).  In humans, SLCO1B1, 1B3, 2B1 and 1A2 have relatively high 
expression in liver.  SLCO1B1, 1B3, and 2B1 transport a diverse range of 
drugs including benzylpenicillin, statins, and estradiol glucuronide (Klaassen 
and Aleksunes, 2010).  Identification of SNPs in the SLCO1B1 gene and 
resulting SLCO1B1 polymorphisms results cause altered disposition of statins 
(Generaux et al., 2011).  Human SLCO mRNA expression is regulated through 
transcription factor-mediated pathways, such as Liver-X-Receptor (LXR), 
Farnesoid-X-Receptor (FXR), Constitutive Androstane Receptor (CAR), 
Pregnane-X-Receptor (PXR) (Svoboda et al., 2011). 
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The ATP-binding cassette (ABC) transporter superfamily facilitates chemical 
efflux; and includes Multidrug Resistance Proteins (ABCB), Multidrug 
Resistance-Associated Proteins (ABCC), Bile Salt-Export Pump (ABCB11), 
and Breast Cancer Resistance Protein (ABCG2).  In liver, ABCC2, ABCG2 
and ABCBs are localized to the canalicular membrane and facilitate biliary 
excretion of chemicals.  ABCC1, 3-6 are localized sinusoidally and/or 
basolaterally, and efflux chemicals from hepatocytes into blood. Similar to 
SLCOs, human ABCC expression is modulated by transcription factors, such 
as Nuclear Factor-E2 related factor 2 (NRF2), CAR, PXR, and FXR (Klaassen 
and Slitt, 2005).   
 
Alterations in transporter expression and function due to hepatic stress have 
been noted and can have significant implications on the fate of numerous 
drugs.  Hepatic steatosis resulting from obesity and/or diabetes resulted in 
significant alterations in transporter expression in hepatocytes, as 
demonstrated in mouse models (Cheng et al., 2008; More and Slitt, 2011; 
More et al., 2012).  As compared to steatosis, cirrhosis is a significant hepatic 
stress with replacement of normal functional tissue by scar tissue, which is 
unable to maintain the functions of the liver.  According to Center for Disease 
Control and prevention (CDC), more than 15,000 Americans die every year 
from alcoholic liver cirrhosis (National Vital Statistics Report, Volume 60, No 3).  
Other major causes of cirrhosis include chronic viral hepatitis, non-alcoholic 
steatohepatitis (NASH), and damaged or blocked bile flow (Anand, 1999).  
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About 30% of cirrhotic patients also suffer from diabetes (Hickman and 
Macdonald, 2007).  Acute, as well as chronic alcohol consumption leads to 
development of insulin resistance, which can progress to diabetes mellitus 
(Kim and Kim, 2012).  Disruption of normal functions of the liver in cirrhosis 
may lead to hepatogenous diabetes (Garcia-Compean et al., 2009).  
Additionally, obesity and diabetes mellitus increase the severity of alcoholic 
liver disease (Raynard et al., 2002).  Owing to interplay between diabetes and 
cirrhosis, the two conditions often co-present clinically (Baig et al., 2001).  
 
Since many human Phase-I and -II biotransformation enzymes are 
coordinately regulated by transcription factors that regulate transporter 
expression, representative cytochrome p450 (CYP), UDP glucuronosyl 
transferase (UGT), and Nad(p)h:quinone oxidoreductase (NQO1) mRNA 
expression was also determined.  The purpose of this study was to determine 
whether alcohol cirrhosis alone, or in combination with diabetes, alter 
transporter expression in intact human liver, as transporters are integral for the 
hepatobiliary clearance of drugs, bile acids, and bilirubin.  Our study has 
included analysis of livers from subjects who presented with steatosis or 
diabetes without cirrhosis, as these diseases are sometimes present in 
alcoholics.  Our findings herein illustrate coordinated alterations in the 
expression of certain SLCO and ABC transporter members in human alcohol 
cirrhotic liver tissues.   
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3.3 Materials and Methods 
 
3.3.1 Human liver tissues.  Liver tissues from normal healthy, alcohol 
cirrhotic, steatotic, and diabetic-cirrhotic (co-existence of alcohol cirrhosis and 
diabetes) subjects were obtained from Liver Tissue Cell Distribution System 
(LTCDS), University of Minnesota (Minneapolis, MN).  Additional liver lysates 
in Trizol reagent from normal and diabetic subjects were purchased from 
Xenotech LLC (Lenexa, KS) and were only analyzed for mRNA expression.  
The details of subject age, gender and ethnicity are mentioned in table 1.  
Exemption approval from the University of Rhode Island Institutional Review 
Board was granted before tissues were procured.    
 
3.3.2 RNA Extraction.  Total RNA from liver was isolated by phenol-
chloroform extraction using RNA Bee (Tel-Test Inc, Friendswood, TX) 
according to the manufacturer’s protocol.  Tissue lysates obtained in Trizol 
were directly homogenized and subject to chloroform extraction.  RNA 
concentration was quantified by absorbance at 260 nm (Nanodrop ND1000, 
Thermo Fisher Scientific, Waltham, MA).  Agarose gel electrophoresis 
followed by UV illumination was used to visualize RNA and confirm integrity.  
 
3.3.3 Quantigene Plex 2.0 assay for mRNA quantification.  Only samples in 
which total RNA looked intact and not degraded were subjected to analysis the 
QuantiGene Plex 2.0 assay (Affymetrix, Santa Clara, CA).  However, a benefit 
to this technology according to the manufacturer is that it allows for detection 
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of partially degraded mRNA transcripts, which is desirable for RNA isolated 
from human tissue.  The protocol for the assay is described elsewhere 
(Aleksunes et al., 2009).  Briefly, 1.1 µg total RNA was incubated with beads 
with capture probe, label extender and blocker.  On day two, the beads were 
washed and incubated with amplifier, and subsequently with label.  Then 
incubation with streptavidin containing substrate was used for detection on 
BioPlex Luminometer.   
 
3.3.4 Tissue fractionation.  Approximately 100mg of tissue was 
homogenized in Sucrose-Tris (ST) buffer (250 mM sucrose, 10 mM Tris-HCl 
buffer, pH 7.4) and containing protease inhibitor cocktail (2 µg/mL, Sigma-
Aldrich, Co, St. Louis, MO).  Homogenates were centrifuged at 100,000 xg for 
60min at 4°C.  The resulting pellet is a typical fraction used to detect 
transporter expression as described by our previous publications as well as 
multiple other research groups (Trauner et al., 1997; Aleksunes et al., 2006; 
Campion et al., 2008; Cheng et al., 2008; Maher et al., 2008).   The 
supernatant was saved as a cytosolic fraction to measure NQO1 and GPX1 
protein expression.  ST buffer (200 µl) was used to re-suspend the resulting 
pellet.  Nuclear fractions from approximately 100 mg of liver tissue were 
isolated using a NE-PER nuclear extraction kit (Thermo Scientific, Rockford, 
IL) according to the manufacturer’s instructions.  Protein concentration of the 
membrane fractions was determined using the DC protein assay (Bio-Rad 
Laboratories, Hercules, CA). 
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3.3.5 Western blot analysis.  Western blots were used to quantify the relative 
expression of transport proteins in human liver tissues, as described in our 
previous publication (More and Slitt, 2011; More et al., 2012).  Briefly, the 
membrane/ nuclear extracts were separated on polyacrylamide gel (10% 
resolving, 4% stacking), transblotted on PVDF membrane, and blocked with 
2% non-fat dry milk in phosphate buffered saline with Tween 20 (PBS/T).  The 
membranes were then incubated with specific primary and secondary antibody, 
and then with ECL+ fluorescence reagent.  The blots were then developed on 
X-ray films; protein bands on the resulting autoradiographs were quantified 
using Quantity One! software v4.6.3 (Biorad, Hercules, CA).  Table 2 
provides the antibody source and western blot conditions.  OATP1B1 and 1B3 
protein expression by Western blot was not determined due to lack of high 
quality commercially available antibodies. 
 
3.3.6 Statistical analysis.  Raw data from mRNA quantification was 
normalized to housekeeping gene hypoxanthine phosphoribosyl transferase 1 
(HPRT1).  Log transformed normalized data was more approximately normally 
distributed as compared with non-transformed data.  Within each gene, 
pairwise comparison of expression between disease groups was tested a one-
way ANOVA followed by a Tukey Honestly Significant Difference (HSD) test. 
Data from protein quantification was plotted as percent expression and 
analyzed by one-way ANOVA followed by Dunnett’s post hoc test.  Difference 
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of p! 0.05 was considered statistically significant.  Asterisks (*) represent a 
statistical difference (p!0.05) from normal non-steatotic livers, and dots (") 
represent outliers.  Hierarchical clustering analysis with Pearson correlation as 
a similarity measurement was also done to discover potential groups of genes 
with high correlation.     
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3.4 Results 
3.4.1 Transporter mRNA expression in liver is altered by alcohol 
cirrhosis and diabetic-cirrhosis.  Alcohol cirrhosis altered mRNA expression 
of some transporters (Fig. 1A).  SLCO1B1 mRNA expression was similar 
among all groups examined.  SLCO1B3 mRNA expression was significantly 
decreased in livers from alcohol cirrhosis patients compared to normal non-
steatotic livers.  In contrast, SLCO2B1 mRNA expression was increased with 
alcohol cirrhosis compared to normal non-steatotic livers.   
In liver, ABCC transporters are localized to the canalicular (ABCC2 and 
ABCG2) or sinusoidal membranes (ABCC1, 3-6) of hepatocytes, and mediate 
organic anion efflux from hepatocytes (Klaassen and Aleksunes, 2010).  
ABCC1, 4 and 5 mRNA expression was increased in alcohol cirrhotic livers 
compared to normal non-steatotic livers (Fig. 1B).  ABCC2 mRNA expression 
remained unchanged between the groups compared, whereas ABCG2 
expression was increased in livers from subjects with alcohol cirrhosis (Fig. 
1B).  Diabetic-cirrhosis decreased ABCC3 expression compared to normal 
non-steatotic livers.  ABCC6 mRNA expression was similar among from 
normal, steatotic, alcohol cirrhotic, diabetic-cirrhotic, and diabetic livers.   
 
3.4.2 Transporter protein expression is altered in livers from subjects 
with steatosis, alcohol cirrhosis, and diabetic-cirrhosis.  Fig. 2 illustrates 
the effect of steatosis, alcoholic cirrhosis, and diabetic-cirrhosis on transporter 
protein expression in fractions from intact human liver tissue (representative 
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blots).  Alcoholic cirrhosis and diabetic-cirrhosis increased ABCC1, 3, and 5 
protein expression compared to normal non-steatotic livers.  ABCC2 protein 
remained unchanged between all the groups.  ABCC4 and ABCG2 protein 
expression was increased in livers with steatosis, alcohol cirrhosis and 
diabetic cirrhosis.  In contrast to other ABC transporters, ABCC6 protein 
expression decreased in livers with alcohol cirrhosis and diabetic cirrhosis.   
 
3.4.3 Alcoholic cirrhosis and diabetic-cirrhosis affect transcription factor 
expression in intact human liver.  Studies in recent years have revealed 
several transcription factor-mediated pathways (e.g. PXR, CAR, and FXR), as 
well as the antioxidant response (e.g. NRF2), are important mediators of 
SLCO and ABC transporter regulation in liver (Klaassen and Aleksunes, 2010).  
Therefore, NRF2, PXR, CAR, and FXR expression was also evaluated and 
correlated with transporter expression.  Fig. 3A depicts the PXR, CAR FXR, 
and NRF2 mRNA expression in human liver.  NRF2 mRNA expression was 
increased in alcohol cirrhotic and diabetic-cirrhotic livers compared to normal 
non-steatotic livers.  PXR mRNA expression was decreased in livers with 
diabetic-cirrhosis, as compared to normal livers.  CAR mRNA expression 
remained unchanged between all groups analyzed.  FXR mRNA expression 
was decreased in livers with alcohol cirrhosis and diabetic-cirrhosis.  
 
3.4.4 Alcohol cirrhosis affects phase-I and phase-II drug metabolizing 
enzymes mRNA expression.  Correspondingly, Figure 3B depicts mRNA 
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expression for representative CYP and UGTs, along with FXR target gene, 
Small Heterodimer Protein (SHP).  UGT1A3 mRNA expression was increased 
in steatotic livers compared to normal livers.  CYP3A4 mRNA expression was 
increased in livers with steatosis, but similar to normal livers in the other 
disease conditions.  CYP2B6 mRNA expression was decreased in livers with 
diabetic-cirrhosis compared to normal non-steatotic livers.  SHP mRNA 
expression was similar among all the disease conditions tested in the study.  
Other CYP and UGT isoforms including CYP2D6, UGT1A1, 1A4 mRNA 
expressions were also studied, and remained unchanged between the groups 
(data not shown). 
 
3.4.5 Alcohol cirrhosis increases NRF2, NQO1, and Glutathione 
Peroxidase protein expression.   NRF2 protein expression in liver fractions 
was correspondingly increased in alcohol cirrhotic and diabetic-cirrhotic livers 
compared to normal non-steatotic livers (Fig. 3C and 3D).  NQO1 and 
Glutathione Peroxidase 1 (GPX1), enzymes, which are regulated via NRF2, 
were also quantified at protein level.  NQO1 protein expression was increased 
in steatotic, alcohol cirrhotic and diabetic-cirrhotic livers compared to normal 
livers, with the most prominent increase present in alcohol cirrhosis.  GPX1 
protein expression was increased in liver fractions from subjects with alcohol 
cirrhosis and diabetic-cirrhosis. 
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3.4.6 Alcohol cirrhosis increases inflammatory cytokine mRNA 
expression.  Fig. 4 demonstrates mRNA expression of inflammatory 
cytokines tumor necrosis factor " (TNF"), and interleukin 1# (IL1#) in livers.  
TNF" mRNA expression was increased in both steatosis and alcohol cirrhosis 
groups, as compared to normal non-steatotic livers.  IL1# expression was 
increased only with steatosis as compared to normal livers.   
 
3.4.7 Hierarchical cluster analysis of transporter and transcription factor 
mRNA expression.  Fig. 5 depicts the correlations between transcription 
factor and transporter mRNA expression.  ABCG2 and SLCO2B1 expression 
were closely related to CAR expression. Similarly, expression of ABCC4, 
ABCC5 and NRF2 were closely related. Expression of ABCC2 and PXR were 
also closely related, and more distantly related to SLCO1B3 and 1B1 
expression.    
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3.5 Discussion 
This study demonstrated predominant increased mRNA and protein of efflux 
transporters, such as ABCG2, ABCC1, 3-5 in intact livers of human subjects 
with alcohol cirrhosis.  Uptake transporter expression was less consistent, with 
decreased SLCO1B3 and increased SLCO2B1 mRNA expression occurring in 
livers with alcoholic cirrhosis.  Transcription factors that regulate transporter 
expression were also correspondingly altered.  NRF2 mRNA and protein 
expression was increased in alcoholic cirrhotic livers, whereas FXR mRNA 
expression was decreased. 
Hierarchical cluster analysis of transcription factors and transporters obtained 
in this study is in agreement with the findings in literature.  In rodents as well 
as in humans, NRF2 is known to regulate expression of efflux transporters 
ABCC2-5 (Klaassen and Slitt, 2005).  In the cluster analysis in the present 
study, ABCC4 and 5 were expressed together with NRF2.  Similarly, 
SLCO2B1 and CAR were expressed together, as observed in rodents (Cheng 
et al., 2005).  ABCC2 and PXR were also clustered together, as also 
described (Klaassen and Slitt, 2005).  SLCO1B1 and 1B3 are reported to be 
regulated by same transcription factors hepatocyte nuclear factor (HNF) 1#, 
aryl hydrocarbon receptor (AHR) and CAR (Klaassen and Aleksunes, 2010),  
and were clustered together in present data.  CAR and PXR activation have 
been shown to increase ABCC2 and 3 expression in hepatocytes (Teng and 
Piquette-Miller, 2005), indicating that these two transporters also have 
significant correlation in expression.  CAR is known to regulate ABCC2, 3 as 
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well as SLCO1B1, indicating significant correlation in the expression of these 
three transporters.   
Transporter expression in human livers with alcohol cirrhosis has not been 
characterized comprehensively before this study.  Rodent models for alcohol-
induced liver disease display steatosis and some degree of fibrosis, but no 
model fully progresses to the human level of cirrhotic liver (Lieber et al., 1965; 
Tsukamoto et al., 1986).  Previous studies with hepatic transporter expression 
are with small sample size and/or different liver pathologies like hepatitis C, 
hepatocellular carcinoma, NASH, or from non-diseased human livers 
(Nishimura and Naito, 2005; Hilgendorf et al., 2007; Ogasawara et al., 2010; 
Doi et al., 2011).  Hepatitis C virus-related cirrhosis was reported to increase 
mRNA and protein expression of ABCC4 in human livers (Ogasawara et al., 
2010), which is consistent with alcohol cirrhosis and diabetic-cirrhosis findings 
from the present study.  Another study reported a patient having lowered 
SLCO1B3 expression in hepatocellular carcinoma nodule (Doi et al., 2011), 
which is consistent with the present data that illustrate decreased SLCO1B3 
mRNA expression in alcohol cirrhosis too.  Efflux transporter expression in 
human livers with primary billiary cirrhosis (PBC) was also similar to alcohol 
cirrhotic livers in this study (Zollner et al., 2003).  ABCC3 protein expression 
was increased in PBC and alcohol cirrhosis.  Uptake transporter SLCO1B1, 
however, remained unchanged with alcohol cirrhosis, but went down with PBC 
(Zollner et al., 2003).  Fatty and non-fatty NASH also enhanced the mRNA and 
protein expression of ABCC1, 4 and 5 in human livers (Hardwick et al., 2011).  
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As other models of liver injury (e.g. acetaminophen, carbon tetrachloride, 
cholestasis) also increase efflux transporter expression, we acknowledge that 
the observation was anticipated.  However, because alcohol cirrhosis plagues 
about 20% of the alcoholic people worldwide, knowing whether aberrant 
transporter and nuclear receptor expression is present in liver is of 
toxicological significance because it can provide mechanistic understanding of 
drug-induced liver injury or altered drug efficacy in patients with alcoholic liver 
disease. 
 
Transporters facilitate absorption, distribution and elimination of xenobiotics, 
as well as endobiotics such as bile acids, cholesterol, and conjugated 
hormones (e.g. estrogens and thyroid hormones) (Klaassen and Aleksunes, 
2010).  Alterations in the transporter expression or polymorphisms have been 
associated with alterations in disposition and adverse effects/ protection 
against adverse effects of certain xenobiotics.  Simvastatin-induced myopathy, 
which is concentration dependent side effect, was found associated with 
SLCO1B1 polymorphism in human subjects (reviewed by (Niemi et al., 2011)).  
In another study with methotrexate, it was observed that variants of SLCO1B1 
were associated with increased clearance and gastrointestinal toxicity as a 
side effect in children with acute lymphoblastic leukemia (Trevino et al., 2009).  
In a different study, mice with increased Abcc3 and 4 expression in liver had 
enhanced metabolite excretion and were protected against acetaminophen 
induced hepatocyte injury (Slitt et al., 2003; Aleksunes et al., 2008) and mice 
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lacking Abcc2, 3 and Abcg2 demonstrate mild hepatotoxicity when 
administered diclofenac (Lagas et al., 2010).  The present study illustrates that 
intact livers from subjects with alcohol cirrhosis have alterations in major drug 
transporter mRNA and protein expression in liver.  As transporters play a vital 
role in drug disposition, the findings in this study imply that subjects with above 
mentioned disease conditions need a consideration while administering drugs 
that form glucuronide, which are pharmacologically active.  
With progression of NAFLD, the expression of Nrf2 and its target genes 
increases, as determined by immunohistochemistry in human livers (Hardwick 
et al., 2010).  Alcohol-induced oxidative stress also activates Nrf2 in human 
hepatocytes (Nussler et al., 2010).  Alcohol induces lipid deposition in liver; 
and metabolism of fatty acids as well as ethanol causes generation of 
oxidative stress in liver (Syn et al., 2009).  Alcohol cirrhotic livers in the current 
study also displayed increased Nrf2 protein levels in nuclear fractions, which is 
likely a response to increased oxidative stress in the alcoholic liver.  PXR is 
indicated in therapeutic applications against inflammatory liver diseases.  PXR 
activation by pregnenolone-16-alpha carbonitrile leads to decreased carbon 
tetrachloride induced fibrogenesis in rats (Marek et al., 2005).  The decreased 
PXR expression may be an indicator that PXR deficiency correlates with 
increased risk for liver disease.  FXR regulates bile acid homeostasis, TG and 
cholesterol metabolism, glucose homeostasis and fibrogenesis in liver 
(reviewed by (Fuchs, 2012)).  FXR activation by bile acids induces PPAR# 
expression, and this increases $-oxidation of fatty acids (Pineda Torra et al., 
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2003).  Thus FXR activation may protect liver from fat deposition in both 
alcoholic, as well as, non-alcoholic liver diseases.  In present study, FXR 
mRNA expression was decreased in alcohol cirrhosis, suggesting that FXR 
suppression might occur during alcoholic liver disease, which could be a 
mechanism for alcoholic liver injury.  Inflammation could be a possible factor 
contributing to the alterations in nuclear receptors analyzed in this study.  
Lipopolysaccharide treatment of mice resulted in decreased PXR signaling 
and target gene expression in mice (Moriya et al., 2012).  Similarly, treatment 
of Huh7 cells with inflammatory cytokines TNF" and IL6 resulted in marked 
decrease in FXR target transporter BSEP (Chen et al., 2012).  As disease 
progression of cirrhosis involves increase in inflammation, decreased mRNA 
expression of PXR/ FXR in alcohol cirrhosis/ diabetic cirrhosis could possibly 
be explained.  Further studies are necessary in order to elucidate why PXR 
and FXR expression is decreased in alcohol cirrhosis, and whether the 
decreased expression contributes to the development of alcohol cirrhosis. 
Elbekai et. al., in 2004 reported that certain Phase-I biotransformation enzyme 
expression was altered expression in livers of cirrhotic subjects.  CYP1A and 
CYP3A showed reduced expression with cirrhosis, whereas CYP2C, 2A and 
2B remained unaltered (Elbekai et al., 2004).  The present data display little or 
no change in CYP isoform mRNA expression.  Similarly, glucuronidation 
activity in liver is reported to be unaltered with cirrhosis (Elbekai et al., 2004). 
The present study had results consistent with this observation – UGT1A1, 1A3, 
1A4, and 2B7 expression was remained unchanged between normal and 
! 69 
alcohol cirrhotic livers, although it should be noted that UGT1A3 was 
decreased in diabetic-cirrhosis livers and UGT2B7 was decreased in diabetic 
livers. 
In summary, we demonstrate that alcohol cirrhosis significantly alters 
transporter expression in human liver, most notably altering ABCC3, ABCC4, 
and, ABCC5, which was associated with altered NRF2, CAR, and FXR mRNA 
expression.  Significant correlations between transporter and nuclear receptor 
expression were observed in the cohort of livers analyzed.  Overall, the data 
herein illustrate alterations in hepatic transporter expression in the alcohol 
cirrhotic liver that correlates to changes in nuclear receptor expression.  
Alterations in nuclear receptor and drug transporter expression in alcoholic 
liver should be given consideration when evaluating altered drug toxicities.   
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3.7 Figure Legends 
Fig. 1. Transporter mRNA expression in livers from normal, steatotic, 
alcohol cirrhotic, diabetic-cirrhosis, and diabetic subjects.  (A) SLCO1B1, 
1B3 and 2B1 mRNA expression, (B) ABCC1-6, and ABCG2 mRNA expression.  
Total RNA was isolated from intact human donor liver tissue (Normal, n=22; 
Steatosis, n=8; Alcohol cirrhosis, n=19; Diabetes, n=20; Diabetic-cirrhosis, 
n=9) and relative mRNA expression was quantified.  Raw data was normalized 
to HPRT1 and log transformed before comparison.  Asterisks (*) represent a 
statistical difference (p!0.05) from normal non-steatotic livers and dots (") 
represent outliers.  SLCO1B3 mRNA expression was decreased, whereas 2B1 
was increased in alcohol cirrhosis compared to normal non-steatotic livers.  
ABCG2, ABCC4 and 5 mRNA expression was increased in livers from donors 
with alcohol cirrhosis compared to normal non-steatotic livers.  ABCC3 
expression decreased in diabetic-cirrhosis livers.   
Fig. 2. Protein expression of transporters in livers from normal, steatotic, 
alcohol cirrhotic, and diabetic-cirrhosis subjects by western blot.  (A) 
Relative ABCC1-6, and ABCG2 protein expression was determined in 
fractions isolated from intact human liver by Western blot.  Lanes 1-5 (normal, 
non-steatotic), 6-10 (steatosis), 11-20 (alcohol cirrhosis), and 21-25 (diabetic-
cirrhosis) represent samples analyzed.  (B) Quantification of western blots.  
Protein bands were quantified using Quantity One! software v4.6.3 (Biorad, 
Hercules, CA).  Asterisks (*) represent a statistical difference (p!0.05) from 
normal non-steatotic livers and dots (") represent outliers.  Steatosis 
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increased ABCC4 and ABCG2 protein expression compared to normal livers.  
ABCC1, 3, 5 protein expression was increased, whereas ABCC6 was 
decreased in alcohol cirrhotic and diabetic-cirrhotic livers as compared to 
normal non-steatotic livers.  ABCC4 and ABCG2 expression was increased in 
livers with steatosis, alcohol cirrhosis and diabetic-cirrhosis. 
Fig. 3. Transcription factor and biotransformation enzyme expression in 
livers from normal, steatotic, alcohol cirrhotic, diabetic-cirrhotic, and 
diabetic subjects.  (A) Relative PXR, CAR, FXR and NRF2 mRNA 
expression in human liver. Total RNA was isolated from intact human donor 
liver tissue (Normal, n=22; Steatosis, n=8; Alcohol cirrhosis, n=19; Diabetes, 
n=20; Diabetic-cirrhosis, n=9) and relative mRNA expression was quantified.  
Alcohol cirrhosis and diabetic cirrhosis increased NRF2, but decreased FXR 
mRNA levels.  Diabetic-cirrhosis also decreased PXR mRNA levels.  (B) 
CYP3A4, 2B6, UGT1A3, and 2B7 mRNA expression in liver.  Total RNA was 
isolated from intact human donor liver tissue (Normal, n=22; Steatosis, n=8; 
Alcohol cirrhosis, n=19; Diabetes, n=20; Diabetic-cirrhosis, n=9).  Steatosis 
increased CYP3A4 and UGT1A3 mRNA expression as compared to normal 
non-steatotic livers.  CYP2B6 mRNA expression was decreased in diabetic 
livers as compared to normal non-steatotic livers.  (C) Relative NRF2, NQO1, 
and GPX1 protein expression in nuclear (NRF2) and cytosolic (NQO1, GPX1) 
fractions in livers of normal, steatotic, cirrhotic and diabetic-cirrhotic subjects.  
Lanes 1-5 (normal, non-steatotic), 6-9 (steatosis), 10-16 (alcohol cirrhosis), 
and 17-21 (diabetic-cirrhosis) represent samples analyzed.  (D) Quantification 
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of NRF2, NQO1, and GPX1 western blots.  Asterisks (*) represent a statistical 
difference (p!0.05) from normal non-steatotic livers and dots (") represent 
outliers.  Nuclear NRF2 (approximately 110 kDa) and cytosolic NQO1, GPX1 
protein (31 kDa and 23 kDa) levels were increased in livers of alcohol cirrhosis 
and diabetic-cirrhosis subjects as compared to normal livers.  NQO1 was also 
increased in steatotic livers.  
Fig. 4. Inflammatory cytokine mRNA expression in livers from normal, 
steatotic, alcohol cirrhotic, diabetic-cirrhotic, and diabetic subjects.  
Inflammatory cytokine tumor necrosis factor " (TNF") and interleukin 1# 
(IL1#) mRNA expression.  Steatosis increased mRNA expression of both 
TNF" and IL1#, and alcohol cirrhosis increased expression of only TNF", as 
compared to normal non-steatotic livers.  
Fig. 5. Hierarchical cluster analysis of different transporters and 
transcription factors.  Target gene expression was normalized to HPRT1 
and log transformed to use for cluster analysis. Cluster analysis was 
performed by using squared Pearson’s correlation ( ) as a similarity measure. 
Genes were clustered as a group with bigger .  ABCG2 and SLCO2B1 
expression were closely related to CAR expression. Similarly, expression of 
ABCC4, ABCC5 and NRF2 were closely related to each other. 
Expression of ABCC2 and PXR were also closely related, and further related 
to SLCO1B3 and 1B1 expression. 
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3.8 Tables 
Table 1: Gender, ethnicity, and age information of the human liver samples used in the study 
No. Condition Gender Ethnicity Age in years 
1 Normal M Unknown 49 
2 Normal M Unknown 45 
3 Normal F African American 61 
4 Normal F Caucasian 57 
5 Normal F Caucasian 76 
6 Normal F Caucasian 39 
7 Normal F Caucasian 55 
8 Normal F Caucasian 49 
9 Normal M African American 48 
10 Normal M Caucasian 21 
11 Normal M Caucasian 35 
12 Normal M Caucasian 59 
13 Normal M Caucasian 44 
14 Normal M Caucasian 69 
15 Normal M Caucasian 55 
16 Normal M Caucasian 73 
17 Normal F Caucasian 60 
18 Normal F Caucasian 51 
19 Normal M Caucasian 56 
20 Normal M Caucasian 69 
21 Normal M Caucasian 22 
22 Normal M Caucasian 62 
23 Steatosis M Caucasian 37 
24 Steatosis M Caucasian 31 
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25 Steatosis M Caucasian 46 
26 Steatosis F Caucasian 48 
27 Steatosis F Unknown 46 
28 Steatosis M Caucasian 46 
29 Steatosis M Caucasian 45 
30 Steatosis M Caucasian 40 
31 Alcohol Cirrhosis  F Caucasian 47 
32 Alcohol Cirrhosis  F Caucasian 47 
33 Alcohol Cirrhosis  F Caucasian 44 
34 Alcohol Cirrhosis  F Caucasian 36 
35 Alcohol Cirrhosis  F Unknown 48 
36 Alcohol Cirrhosis  F Unknown 51 
37 Alcohol Cirrhosis  F Unknown 33 
38 Alcohol Cirrhosis  F Unknown 52 
39 Alcohol Cirrhosis  M Caucasian 52 
40 Alcohol Cirrhosis  M Caucasian 50 
41 Alcohol Cirrhosis  M Caucasian 44 
42 Alcohol Cirrhosis  M Caucasian 48 
43 Alcohol Cirrhosis  M Caucasian 63 
44 Alcohol Cirrhosis  M Caucasian 56 
45 Alcohol Cirrhosis  M Caucasian 55 
46 Alcohol Cirrhosis  M Unknown 42 
47 Alcohol Cirrhosis  M Unknown 33 
48 Alcohol Cirrhosis  M Unknown 46 
49 Alcohol Cirrhosis  M Caucasian 56 
50 Diabetes  F Caucasian 68 
51 Diabetes  F Asian 42 
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52 Diabetes  F African American 49 
53 Diabetes  F Caucasian 51 
54 Diabetes  F Caucasian 39 
55 Diabetes  F Caucasian 72 
56 Diabetes  F Caucasian 46 
57 Diabetes  F Caucasian 74 
58 Diabetes  F Caucasian 53 
59 Diabetes  F Caucasian 38 
60 Diabetes  M Caucasian 57 
61 Diabetes  M Caucasian 48 
62 Diabetes  M African American 44 
63 Diabetes  M Caucasian 66 
64 Diabetes  M Caucasian 55 
65 Diabetes  M Caucasian 74 
66 Diabetes  M Caucasian 39 
67 Diabetes  M Caucasian 70 
68 Diabetes  M Caucasian 46 
69 Diabetes  M Caucasian 33 
70 Diabetic Cirrhosis  M Caucasian 39 
71 Diabetic Cirrhosis  M Caucasian 52 
72 Diabetic Cirrhosis  M Caucasian 36 
73 Diabetic Cirrhosis  M Caucasian 65 
74 Diabetic Cirrhosis  M Caucasian 50 
75 Diabetic Cirrhosis  M Caucasian 57 
76 Diabetic Cirrhosis  M Unknown 56 
77 Diabetic Cirrhosis  M Unknown 62 
78 Diabetic Cirrhosis  M Caucasian 52 
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Table 2: Type, dilution, molecular weight and source of primary antibodies for 
western blot analysis 
Antibody Type Dilution Mol wt Source 
ABCC1 MRPr1 1:2000 ~190 
Dr. G. Scheffer, VU Medical Center, 
Amsterdam 
ABCC2 M2III-5 1:600 ~190 Chemicon International- Millipore, MA 
ABCC3 M3II-2 1:2000 ~180 
Dr. G. Scheffer, VU Medical Center, 
Amsterdam 
ABCC4 M4I-10 1:2000 ~160 
Dr. G. Scheffer, VU Medical Center, 
Amsterdam 
ABCC5 M5I-60 1:1000 ~160 
Dr. G. Scheffer, VU Medical Center, 
Amsterdam 
ABCC6 M6II-68 1:1000 ~165 
Dr. G. Scheffer, VU Medical Center, 
Amsterdam 
ABCG2 BXP-53 1:2000 ~75 
Dr. G. Scheffer, VU Medical Center, 
Amsterdam 
NQO1 Ab2346 1:5000 ~30 Abcam, Cambridge, MA 
GPX1 
AB1679
8 1:2000 ~27 Abcam, Cambridge, MA 
NRF2 
SC1303
2 1:1000 ~110 Santa Cruz Biotech. Inc, Santa Cruz, CA 
GAPDH D16H11 1:2000 ~37 Cell Signaling Technology, Danvers, MA 
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4.1 Abstract: 
Obesity is a global pandemic, spanning over 35% of the US population.  
Various mouse models of obesity have been proposed and are used in the 
pharmacokinetic studies.  Diet-induced obese (DIO) mice are diet containing 
60% kCal fat since the weaning.  These mice are overweight, moderately 
hyperglycemic and mildly hyperinsulinemic.  It was demonstrated that these 
mice have altered hepatic transporter expression.  The purpose of this study 
was to study disposition of environmental chemical Bisphenol-A (BPA) in DIO 
mice and compare it with lean controls.  The DIO mice were administered 
100mg/kg body weight dose of BA-d6 orally, and the blood was collected at 
0.25, 0.5, 1, 2, 4 and 8-hour time points.  The serum was analyzed for BPA 
and its major metabolite monoglucuronide.  DIO mice cleared BPA-
glucuronide from the blood at much faster rate as compared to lean mice.  
Although BPA aglycone levels were high in DIO mice serum, total BPA levels 
remained lower that lean mice owing to extensive metabolism.  However, 
enterohepatic recirculation was increased in DIO mice, causing higher total 
BPA in serum at later time points.  These alterations in BPA disposition can be 
attributed to increase in hepatic apical efflux transporter Abcc2 expression, 
along with increased conjugation enzymes Ugt expression in DIO mice.   
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4.2 Introduction:  
Bisphenol A (BPA) is an industrial chemical used in the polycarbonate plastic 
and epoxy resins manufacture.  Plastic water bottles, food and beverage cans 
and dental sealant liners made with epoxy resins release the monomer BPA in 
the contents of the container in smaller amounts that leads to human exposure 
(1).  Polyvinyl chloride plastics and thermal paper recycling also uses BPA.  
Although consumption through diet and water is the primary source of human 
exposure, BPA can also get into body through skin contact with dust, water 
and air (2).  Owing to use of baby bottles, and other plastic products, infants 
and children have higher exposure as compared to adult population (2).     
There are multitudes of evidences in the literature reporting harmful effects 
after exposure to BPA.  Richter et al., reviewed toxicity of BPA after exposure 
to adults, as well as developmental effects when exposed from gestation 
through puberty (3).  Harmful effects of BPA, depending on varying doses and 
different times of exposure, range from neuroendocrine disturbances, 
behavioral effects, reproductive abnormalities, gonadal development and 
fertility alterations in both genders and developmental effects on metabolism 
and immunity (3).   
As toxic effects of BPA depend largely on dose and route of administration, its 
pharmacokinetics is under investigation in various rodent models as well as 
humans.  According to Center for Disease Control and prevention (CDC), 
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more than 90% of the US population is chronically exposed to BPA (4).  
Therefore, in order to assess the susceptibility of all population groups, 
knowing the metabolism and disposition pathways of BPA becomes important 
(4).   
Absorption of BPA to blood is very rapid and thorough, as peak concentrations 
of total BPA were obtained within 20 minutes of administering orally in rats.  It 
is absorbed from small intestine, and there is conjugation of BPA to BPA 
glucuronide in the enterocytes (5).  Plasma protein binding of BPA is extensive 
with the unbound fraction measuring as low as 0.046 in rats after oral 
administration (6).  Monoglucuronide is the major metabolite of BPA.  When 
studied in human liver microsomes, and in recombinant human UGT isoforms, 
it was demonstrated that UGT2B7 and 2B15 were the isoform primarily 
involved in BPA glucuronidation (7).  In rats, BPA is predominantly conjugated 
by Ugt2b1 isoform (8).  Membrane transporters involved in disposition of BPA-
glucuronide are multidrug resistance associated protein 3 (ABCC3) in humans 
and Abcc2 in rats (9).  As reviewed by Willhite et al (2008), as much as 80% of 
administered BPA is excreted in bile in rodents, as opposed to urine in 
humans, and there is marked enterohepatic recirculation (10).      
Obesity and the complications associated with it are widespread pandemics of 
the modern time.  Dietary and lifestyle changes are causing the positive 
energy balance leading to overweight and obesity (11).  According to National 
Health and Nutrition Examination Survey (NHANES) for 2009-2010, about 
36% of the adult and 17% of the young US population was obese.  Diet-
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induced obese (DIO) mouse is one of the commonly used rodent models of 
obesity.  The mice are fed diet containing high fat content (60% kCal) starting 
from 6 weeks of age.  By 13 weeks of age, the mice have about 15% more 
body fat content as compared to respective lean controls fed 10% kCal fat 
(12).  These mice present with mild to moderate hyperglycemia and 
hyperinsulinemia.   
We previously demonstrated that DIO mice are characterized by alterations in 
the hepatic drug transporter expression (13).  As reviewed by Klaassen and 
Aleksunes, drug transporters are the membrane proteins, which aid in 
exchange of drugs, endogenous chemicals and/or metabolites exchange 
across the cell membrane (14).  Alterations in transporter expression are 
known to cause differences in disposition of certain xenobiotics including 
acetaminophen, ezetimibe, morphine, and raloxifene (15-18).  In the present 
study, we have characterized differential metabolism and disposition of BPA in 
DIO mice.  In order to address the reasons for the altered BPA disposition, we 
have also characterized hepatic conjugation enzyme and intestinal transporter 
expression in DIO mice.    
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4.3 Materials and methods: 
4.3.1 Animals: Twenty one week old C57BL/6 male mice fed 10% (Lean) or 
60% kCal (DIO) fat diet (Research Diets Inc, New Brunswick, NJ) since 
weaning, were purchased from Jackson Laboratories (Bar Harbor, ME).  The 
animals were allowed to acclimate for 2 week, while maintaining the same 
diets.  For the BPA disposition study, the study design is described in table 1.  
Another group of mice (n=6 lean and 6 DIO) were euthanized at 23 weeks of 
age and liver and intestine tissues were collected.   
4.3.2 BPA disposition study: As described in table 1, study used n=6 mice 
per group per time point.  The mice were housed in individual cages, with ad 
libitum food and water.  Deuterated BPA (BPA-d6) solution was prepared as 
previously described (19).  Briefly, the weighed amount of BPA-d6 was 
dissolved in 95% ethanol before dilution in water.  The solution was 
administered by oral gavage to mice to get 100µg/kg body weight.  For each 
time point, the blood was collected from mice and spun to get serum.  
4.3.3 BPA-d6 analysis by LC-ES/MS/MS: The detailed method for the 
detection of BPAd-6 is described elsewhere (20).  Briefly, labeled internal 
standard (13C12) was added to each thawed serum sample.  The samples were 
the purified by supported liquid extraction and analyzed by LC-ES/MS/MS in 
the multiple reaction-monitoring mode by monitoring specific transitions for d-6 
and 13C12 -BPA.  Conjugated BPA was hydrolyzed by using H. pomacia 
glucuronidase/ sulfatase (Sigma Chemical Co., St. Louis, MO) incubation, and 
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then total amount of BPA-d6 was quantified.  Subtraction of total and 
conjugated BPA-d6 values provided conjugated amounts.  Limit of detection 
for BPA-d6 with this method was approximately 0.2nM (19).    
4.3.4 Total RNA extraction and mRNA quantification: Total RNA was 
extracted from liver and intestinal tissues by phenol-chloroform extraction as 
described previously (21).  One microgram of total RNA was converted to 
single-stranded cDNA by using oligo(dT)18 primers.  Quantitative real-time 
PCR with Roche LightCycler 480 was used to quantify mRNA expression 
levels.  Samples were run using SYBR green and 18S was used as a 
housekeeping gene to normalize the raw data.  The primers used are listed in 
the table 2.  All the oligonucleotides were synthesized by Life Technologies 
(Grand Island, NY).   
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4.4 Results and discussion: 
As demonstrated in fig. 1, oral administration of BPA-d6 caused rapid 
absorption.  Cmax was achieved at earliest time point (t=0.25hrs) for both 
aglycone and glucuronide.  Aglycone declined rapidly after achieving Cmax, 
indicating rapid distribution/ conjugation.  AUC values for aglycone were much 
lower as compared to total and glucoronide form, indicating extensive 
metabolism.  When disposition in lean and DIO mice was compared, it was 
observed that total BPA amounts in serum were lower in DIO mice over a 
period of 8 hrs after oral dosing.  Lower amounts of total BPA in serum of DIO 
mice can be attributed to lower amounts of BPA-conjugate, as BPA is 
extensively metabolized.  BPA conjugate measured in this study includes both 
BPA-glucuronide and BPA-sulfate metabolites, however as reviewed 
elsewhere, BPA-glucuronide is the dominant metabolite (10).   
Lower levels of total BPA in DIO mice could result from the combination of 
multiple factors.  This experiment was conducted with parallel dosing of 6 lean 
and 6 DIO mice per time point.  So the blood levels are not from serial draws 
from same animal, rather these are different animals at each time point.  The 
mice had access to food throughout the duration of the study.  As mentioned 
earlier, DIO mice are fed a 60% kCal fat diet, whereas lean mice get diet 
containing only 10% kCal fat.  BPA is a moderately hydrophobic with its n-
octanol/ water partition coefficient more than 3.  Presence of high fat diet in the 
gut lumen may play a role in lowered absorption of orally administered BPA.  
After absorption, the BPA may undergo glucoronidation within the enterocytes.  
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It was reported that rat intestinal microsomal preparations possessed higher 
conjugation activity for BPA as compared to human intestinal microsomes 
(22).  However, little is known about extent to which mouse enterocytes 
glucuronidate BPA.   
Because of hydrophobic nature of BPA, its transport through the membrane is 
thought to occur by passive diffusion (23).  However, there are reports of BPA 
aglycone being a substrate for rat Abcc2, human ABCC2, ABCG2 and ABCC3 
(24).  BPA-glucuronide is a substrate for rat Abcc2, human ABCC3, but is a 
non-substrate/ inhibitor for human ABCC2, ABCB1, ABCG2, rat Abcb1a, 
Abcb1b, and Abcg2 (24).  As reviewed by Willhite et al., BPA-glucuronide is 
preferentially excreted in bile in rats, whereas in urine in humans.  This can be 
attributed to localization of rat Abcc2 on the apical membrane and human 
ABCC3 on the basolateral membrane in hepatocytes (14).   
Figure 2A demonstrates alterations in efflux transporter expression in 
duodenum of lean and DIO mice.  It was demonstrated that DIO mice have 
increased expression of Abcc3 and 4, and decreased expression of Abcb1, 
Abcc2 and Abcg2.  Whether these duodenal transporters will play a role in 
altered disposition of BPA in DIO mice depends on extent of glucuronidation 
that takes place in enterocytes.  In a study with segmented everted rat 
intestine, it was noted that increase in concentration of BPA on mucosal side 
increases transfer of unconjugated form to serosal side (25).  Little to no 
information is available on intestinal BPA glucuronidation in mice.   
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After entering the portal circulation, BPA aglycone or glucuronide, enter the 
liver.  In the hepatocytes, the Ugt1b isoforms specific for BPA will convert it to 
BPA-glucuronide, with minor sulfate conjugate formation.  As demonstrated in 
fig. 2B, DIO mice have increased mRNA expression of Ugt1a1, 3a1 and 3a2, 
and increasing trend in Ugt2a3 and 2b1 as compared to lean mice.  This 
suggests higher glucuronide formation in DIO mice as compared to lean.  
However, the glucuronide levels in the blood remained considerably lower in 
DIO mice as compared to lean.  This can be attributed to possible substrate 
specificity on mouse Abcc2, and its significantly increased expression in DIO 
mice livers (13).  Excretion of BPA-glucuronide in intestine through bile results 
in drop of serum glucuronide levels.  At a later time point, DIO mice show 
slight increase in levels of BPA-glucuronide in blood, caused due to 
enterohepatic recirculation.  When conjugated BPA reaches small intestine, it 
undergoes hydrolysis by intestinal b-glucuronidase enzyme, and release BPA 
aglycone.  This aglycone is then absorbed back into the enterocytes.  Now as 
this concentration of BPA will be much lower than original orally administered 
concentration, the extent of intestinal glucuronidation will me more (25).  After 
intestinal glucuronidation, the conjugate will be preferably transported to 
serosal blood supply with the aid of increased basolateral efflux transporters 
Abcc3 and 4.  This may explain why DIO mice have better enterohepatic 
recirculation of BPA as compared to lean mice.   
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4.5 Conclusion:  
Overall body burden of BPA in DIO mice was significantly less as compared to 
lean mice.  Enhanced expression of hepatic UGTs and apical efflux 
transporter Abcc2 can account for higher formation and excretion of BPA-
glucuronide in feces, which results in lower levels of BPA-glucuronide in 
serum.  Enhanced basolateral efflux and decreased apical efflux transporter 
expression in intestines of DIO mice may contribute to higher enterohepatic 
recirculation as compared to lean mice.      
! 99!
 
4.6 References: 
1. Doerge DR, Twaddle NC, Woodling KA, Fisher JW. Pharmacokinetics 
of bisphenol A in neonatal and adult rhesus monkeys. Toxicol Appl 
Pharmacol 2010;248(1):1-11. 
2. Shelby MD. NTP-CERHR monograph on the potential human 
reproductive and developmental effects of bisphenol A. NTP CERHR 
MON 2008(22):v, vii-ix, 1-64 passim. 
3. Richter CA, Birnbaum LS, Farabollini F, Newbold RR, Rubin BS, 
Talsness CE, Vandenbergh JG, Walser-Kuntz DR, vom Saal FS. In vivo 
effects of bisphenol A in laboratory rodent studies. Reprod Toxicol 
2007;24(2):199-224. 
4. Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. Exposure of the 
U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. 
Environ Health Perspect 2008;116(1):39-44. 
5. Yoo SD, Shin BS, Lee BM, Lee KC, Han SY, Kim HS, Kwack SJ, Park 
KL. Bioavailability and mammary excretion of bisphenol a in Sprague-
Dawley rats. J Toxicol Environ Health A 2001;64(5):417-26. 
6. Kurebayashi H, Betsui H, Ohno Y. Disposition of a low dose of 14C-
bisphenol A in male rats and its main biliary excretion as BPA 
glucuronide. Toxicol Sci 2003;73(1):17-25. 
7. Hanioka N, Naito T, Narimatsu S. Human UDP-glucuronosyltransferase 
isoforms involved in bisphenol A glucuronidation. Chemosphere 
2008;74(1):33-6. 
8. Yokota H, Iwano H, Endo M, Kobayashi T, Inoue H, Ikushiro S, Yuasa 
A. Glucuronidation of the environmental oestrogen bisphenol A by an 
isoform of UDP-glucuronosyltransferase, UGT2B1, in the rat liver. 
Biochem J 1999;340 ( Pt 2):405-9. 
9. Nishikawa M, Iwano H, Yanagisawa R, Koike N, Inoue H, Yokota H. 
Placental transfer of conjugated bisphenol A and subsequent 
reactivation in the rat fetus. Environ Health Perspect 2010;118(9):1196-
203. 
10. Willhite CC, Ball GL, McLellan CJ. Derivation of a bisphenol A oral 
reference dose (RfD) and drinking-water equivalent concentration. J 
Toxicol Environ Health B Crit Rev 2008;11(2):69-146. 
! 100!
11. Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and 
policy implications. Nat Rev Endocrinol 2012. 
12. Bush EN, Shapiro R, Nuss M, Kaszubska W, Trevillyan J, Knourek-
Segel V, Kennedy M, Adler A, Jirousek M, Jacobson P. Adiposity, 
Leptin Resistance, Hyperrphagia, Hyperglycemia, Glucose Intolerance 
and Insulin Resistance in C57BL/6J Mice Fed High Fat Diets. 
Endocrine Society Annual Meeting 2001, Poster Session 2001. 
13. More VR, Slitt AL. Alteration of hepatic but not renal transporter 
expression in diet-induced obese mice. Drug Metab Dispos 
2011;39(6):992-9. 
14. Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol 
transporters: function and regulation. Pharmacol Rev 2010;62(1):1-96. 
15. Lickteig AJ, Fisher CD, Augustine LM, Aleksunes LM, Besselsen DG, 
Slitt AL, Manautou JE, Cherrington NJ. Efflux transporter expression 
and acetaminophen metabolite excretion are altered in rodent models 
of nonalcoholic fatty liver disease. Drug Metab Dispos 
2007;35(10):1970-8. 
16. Hardwick RN, Fisher CD, Street SM, Canet MJ, Cherrington NJ. 
Molecular mechanism of altered ezetimibe disposition in nonalcoholic 
steatohepatitis. Drug Metab Dispos 2012;40(3):450-60. 
17. Trdan Lusin T, Mrhar A, Stieger B, Kullak-Ublick GA, Marc J, Ostanek 
B, Zavratnik A, Kristl A, Berginc K, Delic K and others. Influence of 
hepatic and intestinal efflux transporters and their genetic variants on 
the pharmacokinetics and pharmacodynamics of raloxifene in 
osteoporosis treatment. Transl Res 2012;160(4):298-308. 
18. Hasegawa Y, Kishimoto S, Takahashi H, Inotsume N, Takeuchi Y, 
Fukushima S. Altered expression of ABCC2, ABCC3 and UGT2B1 in 
the liver affects the disposition of morphine and its glucuronide 
conjugate in a rat model of cholestasis. J Pharm Pharmacol 
2009;61(9):1205-10. 
19. Doerge DR, Twaddle NC, Vanlandingham M, Fisher JW. 
Pharmacokinetics of bisphenol A in serum and adipose tissue following 
intravenous administration to adult female CD-1 mice. Toxicol Lett 
2012;211(2):114-9. 
20. Twaddle NC, Churchwell MI, Vanlandingham M, Doerge DR. 
Quantification of deuterated bisphenol A in serum, tissues, and excreta 
from adult Sprague-Dawley rats using liquid chromatography with 
tandem mass spectrometry. Rapid Commun Mass Spectrom 
2010;24(20):3011-20. 
! 101!
21. More VR, Wen X, Thomas PE, Aleksunes LM, Slitt AL. Severe diabetes 
and leptin resistance cause differential hepatic and renal transporter 
expression in mice. Comp Hepatol 2012;11(1):1. 
22. Mazur CS, Kenneke JF, Hess-Wilson JK, Lipscomb JC. Differences 
between human and rat intestinal and hepatic bisphenol A 
glucuronidation and the influence of alamethicin on in vitro kinetic 
measurements. Drug Metab Dispos 2010;38(12):2232-8. 
23. Balakrishnan B, Henare K, Thorstensen EB, Ponnampalam AP, Mitchell 
MD. Transfer of bisphenol A across the human placenta. Am J Obstet 
Gynecol 2010;202(4):393 e1-7. 
24. Mazur CS, Marchitti SA, Dimova M, Kenneke JF, Lumen A, Fisher J. 
Human and rat ABC transporter efflux of bisphenol a and bisphenol a 
glucuronide: interspecies comparison and implications for 
pharmacokinetic assessment. Toxicol Sci 2012;128(2):317-25. 
25. Inoue H, Yuki G, Yokota H, Kato S. Bisphenol A glucuronidation and 
absorption in rat intestine. Drug Metab Dispos 2003;31(1):140-4. 
 
 
! 102!
4.7 Figure legends: 
Figure 1. Serum BPA-d6, conjugates, and total time-concentration profile 
in lean and DIO mice after oral administration of 100mg/kg body weight 
BPA-d6.  Dosing of animals from all six time-points was completed within 45 
minutes.  The serum was extracted and BPA-d6 (before and after incubation 
with glucuronidase/sulfatase mix) was quantified by LC-ES/MS/MS using 13C12 
as an internal standard.  * indicates statistical significance in AUC between 
lean and DIO mice (p<0.05). 
Figure 2. Messenger RNA expression of UDP glucuronosyl transferases 
(Ugts) in liver and efflux transporters in duodenum of lean and DIO mice.  
Total RNA was isolated from liver/ duodenal tissue by phenol-chloroform 
extraction, and mRNA was quantified by Quantitative Real-Time PCR, using 
SYBR green.  A) Canalicular efflux transporters Abcc2, Abcb1, Abcg2 and 
basolateral efflux transporters Abcc3 and 4 mRNA expression in duodenum.  
B) Ugt1a1, 1a6, 2a3, 2b1, 2b5, 3a1, and 3a2 mRNA expression in liver.  
*indicates statistical significance in AUC between lean and DIO mice (p<0.05).   
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4.8 Tables: 
Table 1: Number of animals used in Bisphenol-A (BPA) disposition study#.    
 15 min 30 min 60 min 2 hrs 4 hrs 8 hrs 
Lean 6 6 6 6 6 6 
DIO 6 6 6 6 6 6 
 
#All the animals were age-matched (23 weeks). 
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Table 2: Oligonucleaotide primers used in Quantitative Real-Time PCR$  
mUgt1a1 forward GCTTCTTCCGTACCTTCTGTTG 
mUgt1a1 reverse GCTGCTGAATAACTCCAAGCAT 
mUgt1a6 forward GTTTCTCTTCCTAGTGCTTTGGG 
mUgt1a6 reverse CCTCGTTCACTGAGATGTTCTAC 
mUgt2b1 forward GTGCTGGTGTGGCCTACAG 
mUgt2b1 reverse ATTGCTCGGCCCAATGAGG 
mUgt2a3 forward CGTGTGGCCCTGTGATATGAG 
mUgt2a3 reverse GTGCAGTGGAATACGTTTACTCT 
mUgt2b5 forward ACGAGGCGATCTATCATGGAA 
mUgt2b5 reverse GACCTCCTCCAGTGCATTGAG 
mUgt3a1 forward AAACGCCCCCTTGTCATATG 
mUgt3a1 reverse CCTTCGCTTCTTGGTGAAATG 
mUgt3a2 forward CACTCATGGAGGGATGAACAGT 
mUgt3a2 reverse TGGTGAGCGCAAATGACTCTG 
$Synthesized by Life Technologies (Grand Island, NY)  
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Figure 1: Serum BPA-d6, conjugates, and total time-concentration profile in 
lean and DIO mice after oral administration of 100mg/kg body weight BPA-d6   
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SUMMARY AND CONCLUSION 
1. Constitutive activation of Nrf2 makes mice susceptible to development of 
diet-induced obesity, steatosis and glucose intolerance.   
2. Along with role in combating oxidative stress, it appears that Nrf2 also 
regulates some key events in steatosis of the liver, and more studies are 
needed to clarify the mechanism behind these observations.   
3. Alcohol cirrhosis increases the expression of efflux transporters in 
human liver.  Alterations in expression of these transporters may alter the 
disposition of xenobiotics that are substrates for the transporters.  Expression 
of nuclear factors NRF2, FXR and PXR was also altered and a correlation 
was observed between nuclear factors and transporter expression with 
disease conditions.  Altered disposition abilities of patients with alcohol 
cirrhosis should be taken into consideration when addressing adverse drug 
events and drug-drug interactions. 
4. Diet-induced obesity alters phase II conjugation enzymes and intestinal 
drug transporter expression in mice.  DIO mice have enhanced clearance and 
high enterohepatic recirculation environmental chemical Bisphenol A.  This 
can be attributed to alterations in hepatic phase II conjugation enzymes, 
hepatic transporters and intestinal transporter expression alterations in this 
model. 
5. In summary, two distinct roles of Nrf2 were demonstrated- a role in 
development of steatosis with HFD treatment; and regulation of transporter 
expression in response to disease conditions like alcohol cirrhosis.    
